<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral fumaric acid esters for psoriasis - Atwan, A - 2015 | Cochrane Library</title> <meta content="Oral fumaric acid esters for psoriasis - Atwan, A - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010497.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral fumaric acid esters for psoriasis - Atwan, A - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010497.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010497.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral fumaric acid esters for psoriasis" name="citation_title"/> <meta content="Ausama Atwan" name="citation_author"/> <meta content="Cardiff University" name="citation_author_institution"/> <meta content="John R Ingram" name="citation_author"/> <meta content="Cardiff University" name="citation_author_institution"/> <meta content="ingramjr@cardiff.ac.uk" name="citation_author_email"/> <meta content="Rachel Abbott" name="citation_author"/> <meta content="University Hospital of Wales" name="citation_author_institution"/> <meta content="Mark J Kelson" name="citation_author"/> <meta content="Cardiff University" name="citation_author_institution"/> <meta content="Timothy Pickles" name="citation_author"/> <meta content="Cardiff University" name="citation_author_institution"/> <meta content="Andrea Bauer" name="citation_author"/> <meta content="Universitätsklinikum Carl Gustav Carus" name="citation_author_institution"/> <meta content="Vincent Piguet" name="citation_author"/> <meta content="Cardiff University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010497.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010497.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010497.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010497.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Arthritis, Psoriatic [drug therapy]; Dermatologic Agents [adverse effects, therapeutic use]; Fumarates [*administration &amp; dosage, adverse effects]; Methotrexate [therapeutic use]; Psoriasis [*drug therapy]; Randomized Controlled Trials as Topic; Severity of Illness Index" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010497.pub2&amp;doi=10.1002/14651858.CD010497.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010497\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010497\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010497.pub2",title:"Oral fumaric acid esters for psoriasis",firstPublishedDate:"Aug 10, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010497.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010497.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010497.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010497.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010497.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010497.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010497.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010497.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010497.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010497.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2604 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010497.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0039"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/appendices#CD010497-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/table_n/CD010497StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/table_n/CD010497StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral fumaric acid esters for psoriasis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0002">Ausama Atwan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>John R Ingram</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0004">Rachel Abbott</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0005">Mark J Kelson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0006">Timothy Pickles</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0007">Andrea Bauer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information#CD010497-cr-0008">Vincent Piguet</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information/en#CD010497-sec-0126">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010497.pub2">https://doi.org/10.1002/14651858.CD010497.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010497-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010497-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010497-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010497-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010497-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010497-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010497-abs-0001" lang="en"> <section id="CD010497-sec-0001"> <h3 class="title" id="CD010497-sec-0001">Background</h3> <p>Psoriasis is a chronic inflammatory skin condition that can markedly reduce life quality. Several systemic therapies exist for moderate to severe psoriasis, including oral fumaric acid esters (FAE). These contain dimethyl fumarate (DMF), the main active ingredient, and monoethyl fumarate. FAE are licensed for psoriasis in Germany but used off‐licence in many countries. </p> </section> <section id="CD010497-sec-0002"> <h3 class="title" id="CD010497-sec-0002">Objectives</h3> <p>To assess the effects and safety of oral fumaric acid esters for psoriasis.</p> </section> <section id="CD010497-sec-0003"> <h3 class="title" id="CD010497-sec-0003">Search methods</h3> <p>We searched the following databases up to 7 May 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (Issue 4, 2015), MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We searched five trials registers and checked the reference lists of included and excluded studies for further references to relevant randomised controlled trials. We handsearched six conference proceedings that were not already included in the Cochrane Skin Group Specialised Register. </p> </section> <section id="CD010497-sec-0004"> <h3 class="title" id="CD010497-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of FAE, including DMF monotherapy, in individuals of any age and sex with a clinical diagnosis of psoriasis. </p> </section> <section id="CD010497-sec-0005"> <h3 class="title" id="CD010497-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. Primary outcomes were improvement in Psoriasis Area and Severity Index (PASI) score and the proportion of participants discontinuing treatment due to adverse effects. </p> </section> <section id="CD010497-sec-0006"> <h3 class="title" id="CD010497-sec-0006">Main results</h3> <p>We included 6 studies (2 full reports, 2 abstracts, 1 brief communication, and 1 letter), with a total of 544 participants. Risk of bias was unclear in several studies because of insufficient reporting. Five studies compared FAE with placebo, and one study compared FAE with methotrexate. All studies reported data at 12 to 16 weeks, and we identified no longer‐term studies. When FAE were compared with placebo, we could not perform meta‐analysis for the primary outcome of PASI score because the three studies that assessed this outcome reported the data differently, although all studies reported a significant reduction in PASI scores with FAE. Only 1 small study designed for psoriatic arthritis reported on the other primary outcome of participants discontinuing treatment due to adverse effects (2 of 13 participants on FAE compared with none of the 14 participants on placebo; risk ratio (RR) 5.36, 95% confidence interval (CI) 0.28 to 102.1; 27 participants; very low‐quality evidence). However, these findings are uncertain due to indirectness and a very wide confidence interval. Two studies, containing 247 participants and both only reported as abstracts, allowed meta‐analysis for PASI 50, which showed superiority of FAE over placebo (RR 4.55, 95% CI 2.80 to 7.40; low‐quality evidence), with a combined PASI 50 of 64% in those given FAE compared with a PASI 50 of 14% for those on placebo, representing a number needed to treat to benefit of 2. The same studies reported more participants achieving PASI 75 with FAE, but we did not pool the data because of significant heterogeneity; none of the studies measured PASI 90. One study reported significant improvement in participants' quality of life (QoL) with FAE, measured with Skindex‐29. However, we could not compute the mean difference because of insufficient reporting in the abstract. More participants experienced adverse effects, mainly gastrointestinal disturbance and flushing, on FAE (RR 4.72, 95% CI 2.45 to 9.08; 1 study, 99 participants; moderate‐quality evidence), affecting 76% of participants given FAE and 16% of the placebo group (representing a number needed to treat to harm of 2). The other studies reported similar findings or did not report adverse effects fully. </p> <p>One study of 54 participants compared methotrexate (MTX) with FAE. PASI score at follow‐up showed superiority of MTX (mean Difference (MD) 3.80, 95% CI 0.68 to 6.92; 51 participants; very low‐quality evidence), but the difference was not significant after adjustment for baseline disease severity. The difference between groups for the proportion of participants who discontinued treatment due to adverse effects was uncertain because of imprecision (RR 0.19, 95% CI 0.02 to 1.53; 1 study, 51 participants; very low‐quality evidence). Overall, the number of participants experiencing common nuisance adverse effects was not significantly different between the 2 groups, with 89% of the FAE group affected compared with 100% of the MTX group (RR 0.89, 95% CI 0.77 to 1.03; 54 participants; very low‐quality evidence). Flushing was more frequent in those on FAE, with 13 out of 27 participants affected compared with 2 out of 27 given MTX. There was no significant difference in the number of participants who attained PASI 50, 75, and 90 in the 2 groups (very low‐quality evidence) whereas this study did not measure the effect of treatments on QoL. The included studies reported no serious adverse effects of FAE and were too small and of limited duration to provide evidence about rare or delayed effects. </p> </section> <section id="CD010497-sec-0007"> <h3 class="title" id="CD010497-sec-0007">Authors' conclusions</h3> <p>Evidence suggests that FAE are superior to placebo and possibly similar in efficacy to MTX for psoriasis; however, the evidence provided in this review was limited, and it must be noted that four out of six included studies were abstracts or brief reports, restricting study reporting. FAE are associated with nuisance adverse effects, including flushing and gastrointestinal disturbance, but short‐term studies reported no serious adverse effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010497-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010497-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010497-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010497-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010497-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010497-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010497-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010497-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010497-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010497-abs-0003" lang="en"> <h3>Oral fumaric acid esters for the treatment of psoriasis</h3> <p><b>Background</b> </p> <p>Psoriasis is a long‐term inflammatory skin condition that can markedly reduce the quality of life of affected individuals. Treatments taken by mouth (oral treatments), such as methotrexate, ciclosporin, and acitretin, are commonly prescribed to people with moderate to severe psoriasis. Oral fumaric acid esters (FAE) are licensed for the treatment of psoriasis in Germany but remain unlicensed in most other countries. This means that there are different treatment options offered to people in different countries. </p> <p><b>Review question</b> </p> <p>What is the available evidence for the benefits and risks of using FAE for treating psoriasis? </p> <p><b>Study characteristics</b> </p> <p>Our review included six randomised control trials (RCTs) that involved 544 participants. Five RCTs compared FAE with placebo, and one compared FAE with methotrexate. The outcomes we were interested in measuring were the Psoriasis Area and Severity Index (PASI), which is a psoriasis severity score, and the proportion of participants who discontinued treatment because of adverse (side) effects that are common but sufficiently serious that the drug had to be stopped, such as severe diarrhoea, infections, or cutaneous malignancy. </p> <p><b>Key results</b> </p> <p>It was difficult to pool and compare results because outcome measures differed between the studies. Three studies reported significant benefit with FAE when compared with placebo after 12 to 16 weeks of treatment, but we could not combine these results in a statistical analysis to show the overall difference. The included studies did not fully examine the chance of discontinuing FAE treatment because of adverse effects, which is uncertain. One study showed that individuals on FAE are nearly five times more likely to develop nuisance adverse effects; the most common were diarrhoea and abdominal cramps, flushing, reversible protein loss in the urine, and raised levels of eosinophil blood cells. Two RCTs were similar enough to allow the combination of their results and found that FAE were better than placebo when measured by the proportion of individuals who experienced at least a 50% improvement in their psoriasis severity score. One study reported improvement of individuals' quality of life with FAE in comparison with placebo, but the significance of this difference could not be calculated. The benefit of FAE was similar to methotrexate after 12 weeks when changes in disease severity from the start to the end of the trial were compared. The number of individuals experiencing nuisance adverse effects with these two treatments was not significantly different. The included studies, which were too small and of limited duration to provide evidence about rare or delayed effects, reported no serious adverse effects of FAE. </p> <p><b>Quality of the evidence</b> </p> <p>The risk of study bias, which means any factors that may systematically deviate away from the true findings, was unclear in most studies. This may be because most of the studies were conducted decades ago or were incompletely reported. Several analyses comparing FAE with placebo and methotrexate were limited because the studies were small or did not provide enough information to establish how these treatments compare with each other. Therefore, the overall quality of the evidence was low when comparing FAE with placebo and very low when comparing FAE with methotrexate. </p> <p>Future RCTs should use standard psoriasis outcome measures, including a validated quality of life scale, to enable the comparison and combination of results. They should be longer in duration or have longer follow‐up phases to provide evidence about any delayed adverse effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010497-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010497-sec-0111"></div> <h3 class="title" id="CD010497-sec-0112">Implications for practice</h3> <section id="CD010497-sec-0112"> <p>The results of this review should be interpreted with caution because of the relatively small number of participants treated in the qualifying randomised controlled trials (RCTs) and lack of meta‐analyses due to outcome measure heterogeneity in the pre‐Psoriasis Area and Severity Index (PASI) era when some studies were conducted. The limited data obtained from this review provide evidence that oral fumaric acid esters (FAE) are superior to placebo and may be similar in efficacy to methotrexate (MTX). Because of the different ways of reporting changes in PASI scores in studies comparing FAE with placebo, we could only establish the magnitude of benefit for PASI 50. This was 4.5 times more likely to be achieved with FAE after 12 to 16 weeks, with a number needed to treat to benefit of 2. The single study comparing FAE with MTX demonstrated a similar reduction in mean PASI scores from baseline after 12 weeks, with a 7.6‐point reduction for the FAE group compared with a 7.8‐point reduction for those given MTX. Data from only one relatively small study, in which all participants had psoriatic arthritis, suggest that FAE are not associated with a higher rate of treatment discontinuation compared with placebo. However, this is at odds with clinical experience and the results of the prospective observational study by <a href="./references#CD010497-bbs2-0067" title="WalkerF , AdamczykA , KellererC , BelgeK , BruckJ , BernerT , et al. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life. British Journal of Dermatology2014;171(5):1197‐1205. [MEDLINE: 24813676] ">Walker 2014</a>. The concomitant psoriatic arthritis may have affected this finding, so larger studies of participants selected primarily with cutaneous psoriasis are needed to provide a definitive answer. Commonly reported adverse effects associated with FAE include gastrointestinal symptoms (58% of participants in 1 study), flushing (42%, 48%, and 95% in 3 studies), eosinophilia (18.5% and 38.5% in 2 studies), and reversible proteinuria (29.6% in 1 study). However, the RCTs examined did not report long‐term follow‐up data, so the review cannot comment on long‐term safety of FAE for psoriasis, which is important because FAE may be taken for several years in routine clinical practice. </p> </section> <h3 class="title" id="CD010497-sec-0113">Implications for research</h3> <section id="CD010497-sec-0113"> <p>This review has highlighted several important gaps in the evidence base for the treatment of psoriasis with FAE. One of the main issues is outcome measure heterogeneity as some included RCTs were conducted prior to PASI and quality of life becoming the accepted efficacy measures for psoriasis. This will permit meta‐analysis of efficacy data. Comparison with active controls, such as methotrexate, is to be encouraged because these are well established as effective, licensed systemic therapies. The relative efficacy of FAE compared with other systemic psoriasis therapies is also important to establish in the context of the relatively high cost of FAE in most countries. This may be addressed by the ongoing trials, which aim to compare FAE with different active comparators, such as acitretin and biologic therapies (etanercept, adalimumab, and secukinumab). It is worth noting that the status of some of these ongoing trials is unknown (see <a href="./references#CD010497-bbs1-0003" title="">Ongoing studies</a>), so it is unclear whether they were ever completed or whether there might be any issue of publications bias. </p> <p>The current RCTs available have not fully established the timescale in which FAE produce benefit in psoriasis. There is now consensus regarding gradual dose increments for FAE (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>) following treatment initiation, which should allow RCTs to compare speed of FAE action with other systemic therapies. Hence, an important future clinical trial would be a comparison of FAE with MTX both dosed using standardised increments and ensuring 12 weeks of treatment at the maximum dose prior to measuring the primary efficacy outcomes of PASI 75 and quality of life, as well as clear reporting of treatment discontinuation due to adverse effects. </p> <p>This review also highlighted problems in the reporting of AE data, with much of this data either absent or not reported to Consolidated Standards of Reporting Trials (CONSORT) (<a href="http://www.consort-statement.org/" target="_blank">www.consort‐statement.org</a>). Following these clinical trial standards and ensuring consistency in reported outcomes based on the Core Outcome Measures in Effectiveness Trials (COMET) initiative are necessary to enhance the quality and robustness of evidence. Following the schedule of dose increments according to the European S3 guidelines will allow an accurate measure of adverse effects associated with FAE and the rate of treatment discontinuation because of these adverse effects. There is still a need to establish long‐term safety of FAE with a large enough patient cohort to detect rare adverse effects; this evidence should be available in the relatively near future from registers of biologic interventions for psoriasis that contain a systemic medications arm, such as the UK British Association of Dermatologists Biologic Interventions Register (BADBIR) database (<a href="./references#CD010497-bbs2-0025" title="BurdenAD , WarrenRB , KleynCE , McElhoneK , SmithCH , ReynoldsNJ , et al. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology2012;166(3):545‐54. [MEDLINE: 22356636] ">Burden 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010497-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010497-sec-0029"></div> <div class="table" id="CD010497-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FAE compared with placebo for psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FAE compared with placebo for psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriasis<br/> <b>Setting:</b> 2 reports from the Netherlands, 1 from Poland, and 2 international multicentre studies.<br/> <b>Intervention:</b> FAE<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FAE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis))</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>PASI score reduced from a mean of 21.57 to 10.77 (FAE) and remained constant (placebo) (1 study, 99 participants; P &lt; 0.0001); median reduction of 71% (FAE) and 6% (placebo) (1 study, 144 participants; P &lt; 0.001); and median reduction of 67.8% (FAE) and 10.2% (placebo) (1 study, 175 participants; P &lt; 0.001) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All 3 studies reported significant benefit with FAE at week 12 (1 study) and week 16 (2 studies), but data could not be pooled in a meta‐analysis because of different ways of PASI score reporting </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs leading to treatment discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 participants withdrew from the FAE group (n = 13) compared with no dropouts in the placebo group (n = 14) (RR 5.36, 95% CI 0.28 to 102.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW³<sup>,</sup> ⁴ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome reported at week 16. Unclear if any of the reported AEs were 'serious'</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL)<br/> assessed with Skindex‐29 (range 0 to 100; higher scores indicate lower level of QoL) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean scores reduced from 54.7 at baseline to 27 at week 16 in the FAE group (n = 105) and from 54.0 to 51.1 in the placebo group (n = 70) (P &lt; 0.001) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The reporting abstract did not provide the statistical values needed to calculate the mean difference with 95% CI </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common nuisance AEs (not leading to treatment discontinuation)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.72<br/> (2.45 to 9.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Most commonly stomach‐ache or cramps, diarrhoea, and flushing</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 100<br/> (39 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 50</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.55<br/> (2.80 to 7.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>247<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The meta‐analysis included participants who received 720 mg DMF</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 100<br/> (39 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI 75</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>PASI 75 was attained by 39% of participants in the FAE group (n = 105) and 1% of those on placebo (n = 70) (1 study, week 16); and by 42% on FAE (n = 36) compared with 11% on placebo (n = 36) (1 study, week 12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported to be a statistically significant difference, but data were not pooled because of significant heterogeneity (I² statistic = 77%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI 90 ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in the included studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AEs:</b> adverse effects; <b>CI:</b> confidence interval; <b>DMF:</b> dimethyl fumarate; <b>FAE:</b> oral fumaric acid esters; <b>PASI:</b> Psoriasis Area and Severity Index; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial; <b>OR:</b> odds ratio; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to risk of publication bias; data were obtained from abstract(s); full report(s) not available.<br/> ²Downgraded one level due to limitations in design; high risk of performance and detection bias.<br/> ³Downgraded one level due to indirectness; the study was designed for psoriatic arthritis where all participants also had psoriasis so may not be directly applicable to those with moderate to severe psoriasis.<br/> ⁴Downgraded two levels for imprecision; small sample size and very wide confidence interval that included the possibility of an effect in either direction (crosses line of no effect).<br/> ⁵Downgraded one level due to risk of bias; insufficient reporting. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010497-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FAE compared with MTX for psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FAE compared with MTX for psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriasis<br/> <b>Setting:</b> Departments of Dermatology, Rotterdam and Eindhoven, the Netherlands.<br/> <b>Intervention:</b> FAE<br/> <b>Comparison:</b> MTX </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with MTX</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FAE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis))</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PASI score was 6.7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PASI score in the intervention group was 3.8 more (0.68 more to 6.92 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW ¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI score was measured at week 12. The study reported no significant difference between FAE and MTX based on mean change from baseline </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AEs leading to treatment discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/> (0.02 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (FAE = 26; MTX = 25). The main reasons were elevated liver enzymes with MTX and diarrhoea with FAE. No serious AEs occurred in either group </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/> (0 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL was not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common nuisance AEs (not leading to treatment discontinuation)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.77 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only flushing was significantly more reported with FAE. Occurance of other AEs including laboratory findings were not significantly different </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<br/> (77 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 50</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.41 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (MTX = 25; FAE = 26)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 100<br/> (25 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 75</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/> (0.28 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (MTX = 25; FAE = 26)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 100<br/> (7 to 55) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 90</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.05 to 4.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (MTX = 25; FAE = 26)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/> (0 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AEs:</b> adverse effects; <b>CI:</b> confidence interval; <b>FAE:</b> oral fumaric acid esters; <b>PASI:</b> Psoriasis Area and Severity Index; <b>MTX</b> : methotrexate; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial; <b>OR:</b> odds ratio; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level for imprecision due to small sample size.<br/> ²Downgraded one level for study design due to the dose of MTX.<br/> ³Downgraded one level for study design due to study being open label. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010497-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010497-sec-0030"></div> <p>A glossary of technical terms is available in <a href="#CD010497-tbl-0003">Table 1</a>. </p> <div class="table" id="CD010497-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Term</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Description</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adaptive immune system</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immune cells that recognise specific infectious agents and secrete inflammatory cytokines in response </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alkaline phosphatase</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme made mostly in the liver and bones, which may indicate liver damage or bone disease if raised in the blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Angiogenic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Promoting new blood vessel formation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Apoptosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death of a cell</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arthralgia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Joint pain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atherosclerosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Build up of fibrous and fatty material inside the arteries</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Axial skeleton</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The group of bones found along the central axis of the human body, such as the spine</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bilirubin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A yellow‐orange compound produced by the breakdown of haemoglobin from red blood cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biologic treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of drug engineered to alter a specific element of the inflammatory cascade</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemokines</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small protein molecules secreted by cells that attract other inflammatory cells to the area </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Contraindication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A situation that serves as a reason to withhold a certain treatment or procedure because it may be harmful to a patient </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Creatinine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chemical waste product that comes from diet and normal breakdown of muscles and is excreted by the kidneys. It may indicate impaired kidney function if raised in the blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cytokines</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small protein molecules secreted by cells to communicate with neighbouring cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dendritic cells</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of immune cell that act as a messenger between the innate and adaptive immune systems </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eosinophil</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A cell of the immune system that combats parasite infections and is also involved in reactions to some drugs </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eosinophilia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased number of eosinophils in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythrocytes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Red blood cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fumarates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Organic compounds widely found in nature that play a role in citric acid (Krebs) cycle</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gamma glutamyltransferase</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme produced by many tissues, mainly the liver; if raised, it may indicate liver disease </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immunosuppressive</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in the activity of the immune system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A protective response to injury mediated by cells of the immune system, characterised in the skin by redness, heat, swelling, and pain or itch </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Innate immune system</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immune cells and proteins, such as complement, that fight infectious agents in a non‐specific way </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leucocytes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White blood cells that are part of the immune system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leukocytopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased number of white blood cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The position of a gene on a chromosome</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lymphocyte</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of white blood cell involved in the adaptive immune system, which can be subdivided into T cells and B cells </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lymphocytopenia or lymphopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased number of lymphocytes in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major histocompatibility complex</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cell surface molecules involved in recognition of pathogens and tolerance to an individual's own proteins </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Platelet</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of circulating blood cell that helps to form blood clots and stop bleeding (also called thrombocytes) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proteinuria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The presence of abnormal quantities of protein in the urine</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psoriasis Area and Severity Index (PASI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A measure of psoriasis severity that includes the extent of body surface area involvement and the maximum thickness, redness, and scaliness of the plaques. Scores range from 0 to 72, and a higher score indicates more severe disease </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scaly</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silvery‐white flakes of skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum creatinine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The level of creatinine in the blood plasma</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>T (helper) cell</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of white blood cell involved in the adaptive immune system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased number of platelets in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transaminases</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enzymes normally found in the liver and heart, which may indicate liver or heart disease if raised in the blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Triglycerides</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of fat in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinalysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine analysis</p> </td> </tr> </tbody> </table> </div> <section id="CD010497-sec-0031"> <h3 class="title" id="CD010497-sec-0031">Description of the condition</h3> <p>Psoriasis is a chronic inflammatory skin disease (<a href="./references#CD010497-bbs2-0056" title="ParisiR , SymmonsDP , GriffithsCE , AshcroftDM , on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology2013;133(2):377‐85. [DOI: 10.1038/jid.2012.339; MEDLINE: 23014338] ">Parisi 2012</a>), which can be divided into a number of subtypes. The most common subtype is chronic plaque psoriasis, which presents as well‐defined red, scaly plaques typically on the elbows, knees, and scalp (<a href="./references#CD010497-bbs2-0045" title="LebwohlM . Psoriasis. Lancet2003;361(9364):1197‐204. [MEDLINE: 12686053] ">Lebwohl 2003</a>). Other subtypes include flexural psoriasis, in which red plaques are located in the skin creases; guttate psoriasis, in which there are multiple small plaques, particularly on the trunk; generalised pustular psoriasis, involving multiple skin pustules; and erythrodermic psoriasis covering nearly all of the skin surface (<a href="./references#CD010497-bbs2-0045" title="LebwohlM . Psoriasis. Lancet2003;361(9364):1197‐204. [MEDLINE: 12686053] ">Lebwohl 2003</a>). Diagnosis is based on typical clinical features; a skin biopsy can also be helpful if there is diagnostic uncertainty (<a href="./references#CD010497-bbs2-0062" title="SmithCH , BarkerJN . Psoriasis and its management. BMJ2006;333(7564):380‐4. [MEDLINE: 16916825] ">Smith 2006</a>). Psoriatic nail changes, including onycholysis and nail pitting, occur in about 40% of people with psoriasis (<a href="./references#CD010497-bbs2-0020" title="AugustinM , OgilvieA . Methods of outcomes measurement in nail psoriasis. Dermatology2010;221(Suppl 1):23‐8. [MEDLINE: 20733312] ">Augustin 2010</a>). </p> <section id="CD010497-sec-0032"> <h4 class="title">Epidemiology</h4> <p>Psoriasis occurs world wide and has a higher prevalence in countries further from the equator (<a href="./references#CD010497-bbs2-0056" title="ParisiR , SymmonsDP , GriffithsCE , AshcroftDM , on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. Journal of Investigative Dermatology2013;133(2):377‐85. [DOI: 10.1038/jid.2012.339; MEDLINE: 23014338] ">Parisi 2012</a>). In the United Kingdom (UK), it affects about 2% of the population (<a href="./references#CD010497-bbs2-0062" title="SmithCH , BarkerJN . Psoriasis and its management. BMJ2006;333(7564):380‐4. [MEDLINE: 16916825] ">Smith 2006</a>). Psoriasis can develop at any age; the mean age of onset may have two peaks, with the first in young adults and a second peak in about the sixth decade of life (<a href="./references#CD010497-bbs2-0044" title="LangleyRGB , KruegerGG , GriffithsCEM . Psoriasis: epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases2005;64(Suppl II):18‐23. [MEDLINE: 15708928] ">Langley 2005</a>). It probably affects men and women about equally (<a href="./references#CD010497-bbs2-0035" title="GriffithsCE , BarkerJN . Pathogenesis and clinical features of psoriasis. Lancet2007;370(9583):263–71. [MEDLINE: 17658397] ">Griffiths 2007</a>). </p> <p>The cause of psoriasis is thought to be a combination of genetic and environmental risk factors (<a href="./references#CD010497-bbs2-0062" title="SmithCH , BarkerJN . Psoriasis and its management. BMJ2006;333(7564):380‐4. [MEDLINE: 16916825] ">Smith 2006</a>). A family history of psoriasis increases the risk of developing the condition, but in studies of twins, psoriasis in one identical twin does not always predict psoriasis in the other (<a href="./references#CD010497-bbs2-0028" title="DuffyDL , SpelmanLS , MartinNG . Psoriasis in Australian twins. Journal of the American Academy of Dermatology1993;29(3):428‐34. [MEDLINE: 8349859] ">Duffy 1993</a>). Environmental exposures can precipitate psoriasis in some cases, such as streptococcal throat infections leading to guttate psoriasis (<a href="./references#CD010497-bbs2-0065" title="TelferNR , ChalmersRJ , WhaleK , ColmanG . The role of streptococcal infection in the initiation of guttate psoriasis. Archives of Dermatology1992;128(1):39‐42. [MEDLINE: 1739285] ">Telfer 1992</a>), and medications, including beta‐blockers, may trigger chronic plaque psoriasis (<a href="./references#CD010497-bbs2-0023" title="BasavarajKH , AshokNM , RashmiR , PraveenTK . The role of drugs in the induction and/or exacerbation of psoriasis. International Journal of Dermatology2010;49(12):1351‐61. [MEDLINE: 21091671] ">Basavaraj 2010</a>). Skin trauma (e.g., due to surgery) can trigger psoriasis at the surgical site, an observation known as the Koebner phenomenon (<a href="./references#CD010497-bbs2-0035" title="GriffithsCE , BarkerJN . Pathogenesis and clinical features of psoriasis. Lancet2007;370(9583):263–71. [MEDLINE: 17658397] ">Griffiths 2007</a>). </p> <p>Possible links with smoking, alcohol consumption, obesity, and stress remain more controversial, because these may be secondary consequences rather than primary causes (<a href="./references#CD010497-bbs2-0040" title="HuertaC , RiveroE , RodriguezLA . Incidence and risk factors for psoriasis in the general population. Archives of Dermatology2007;143(12):1559‐65. [MEDLINE: 18087008] ">Huerta 2007</a>). </p> <p>Psoriasis is associated with psoriatic arthritis, an inflammatory arthritis that may involve the axial skeleton or more peripheral joints (<a href="./references#CD010497-bbs2-0064" title="TaylorW , GladmanD , HelliwellP , MarchesoniA , MeaseP , MielantsH , et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis &amp; Rheumatology2006;54(8):2665‐73. [PUBMED: 16871531] ">Taylor 2006</a>). Nail involvement has been shown to increase the risk of psoriatic arthritis (<a href="./references#CD010497-bbs2-0035" title="GriffithsCE , BarkerJN . Pathogenesis and clinical features of psoriasis. Lancet2007;370(9583):263–71. [MEDLINE: 17658397] ">Griffiths 2007</a>). Population studies suggest that severe psoriasis may be an independent cardiovascular risk factor (<a href="./references#CD010497-bbs2-0046" title="MehtaNN , AzfarRS , ShinDB , NeimannAL , TroxelAB , GelfandJM . Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. European Heart Journal2010;31(8):1000–6. [MEDLINE: 20037179] ">Mehta 2010</a>). </p> </section> <section id="CD010497-sec-0033"> <h4 class="title">Pathogenesis</h4> <p>Psoriasis is thought to be mediated by cells of the immune system (<a href="./references#CD010497-bbs2-0021" title="BakerBS , SwainAF , FryL , ValdimarssonH . Epidermal T lymphocytes and HLA‐DR expression in psoriasis. British Journal of Dermatology1984;110(5):555‐64. [PUBMED: 6232938] ">Baker 1984</a>). This is supported by resolution of psoriasis after bone marrow transplants from another donor (<a href="./references#CD010497-bbs2-0029" title="EedyDJ , BurrowsD , BridgesJM , JonesFG . Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ1990;300(6729):908. [MEDLINE: 2337714] ">Eedy 1990</a>), the benefit obtained by immunosuppressive treatments, and genetic studies (<a href="./references#CD010497-bbs2-0045" title="LebwohlM . Psoriasis. Lancet2003;361(9364):1197‐204. [MEDLINE: 12686053] ">Lebwohl 2003</a>). PSORS1, located on chromosome 6, is the disease susceptibility gene locus most strongly linked with psoriasis (<a href="./references#CD010497-bbs2-0066" title="TrembathRC , CloughRL , RosbothamJL , JonesAB , CampRD , FrodshamA , et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome‐wide search in psoriasis. Human Molecular Genetics1997;6(5):813‐20. [PUBMED: 9158158] ">Trembath 1997</a>). It contains genes encoding the major histocompatibility complex (<a href="./references#CD010497-bbs2-0053" title="NestleFO , KaplanDH , BarkerJ . Psoriasis. New England Journal of Medicine2009;361(5):496‐509. [MEDLINE: 19641206] ">Nestle 2009</a>). </p> <p>Cells of both the innate and adaptive immune systems are involved; in particular, type helper 1 and type helper 17 cells are important components of the immune cell cascade that results in psoriasis (<a href="./references#CD010497-bbs2-0053" title="NestleFO , KaplanDH , BarkerJ . Psoriasis. New England Journal of Medicine2009;361(5):496‐509. [MEDLINE: 19641206] ">Nestle 2009</a>). These cells secrete cytokines, such as tumour necrosis factor‐alpha (TNF‐α) and interleukin‐17, which cause skin inflammation (<a href="./references#CD010497-bbs2-0053" title="NestleFO , KaplanDH , BarkerJ . Psoriasis. New England Journal of Medicine2009;361(5):496‐509. [MEDLINE: 19641206] ">Nestle 2009</a>). Several biologic treatments, such as anti‐TNF‐α therapies, have been developed to specifically target elements of the inflammatory cascade (<a href="./references#CD010497-bbs2-0063" title="SmithCH , AnsteyAV , BarkerJN , BurdenAD , ChalmersRJ , ChandlerDA , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology2009;161(5):987‐1019. [MEDLINE: 19857207] ">Smith 2009</a>). </p> <p>However, pathogenic pathways in psoriasis are not limited to the immune system: keratinocytes, which are non‐immune cells that form the skin barrier, also play a role by secreting chemokines that attract immune cells to the area (<a href="./references#CD010497-bbs2-0053" title="NestleFO , KaplanDH , BarkerJ . Psoriasis. New England Journal of Medicine2009;361(5):496‐509. [MEDLINE: 19641206] ">Nestle 2009</a>). In addition, tissue samples have demonstrated that new blood vessel formation is a characteristic finding within psoriatic plaques, so angiogenic mediators, such as vascular endothelial growth factor, represent another potential psoriasis pathway (<a href="./references#CD010497-bbs2-0037" title="HeidenreichR , RockenM , GhoreschiK . Angiogenesis drives psoriasis pathogenesis. International Journal of Experimental Pathology2009;90(3):232‐48. [MEDLINE: 19563608] ">Heidenreich 2009</a>). </p> <p>However, understanding of pathogenesis remains incomplete.</p> </section> <section id="CD010497-sec-0034"> <h4 class="title">Impact</h4> <p>Psoriasis is a stigmatising condition, and it can have a major impact on quality of life, equivalent to conditions such as cancer, heart disease, and diabetes (<a href="./references#CD010497-bbs2-0058" title="RappSR , FeldmanSR , ExumML , FleischerABJr , ReboussinDM . Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology1999;41(3 Pt 1):401‐7. [MEDLINE: 10459113] ">Rapp 1999</a>). The impact of psoriasis on appearance and function can greatly affect occupational, psychological, and social elements of quality of life (<a href="./references#CD010497-bbs2-0042" title="KimballAB , JacobsonC , WeissS , VreelandMG , WuY . The psychosocial burden of psoriasis. American Journal of Clinical Dermatology2005;6(6):383‐92. [MEDLINE: 16343026] ">Kimball 2005</a>). The condition may profoundly restrict personal life choices (<a href="./references#CD010497-bbs2-0068" title="WarrenRB , KleynCE , GulliverWP . Cumulative life course impairment in psoriasis: patient perception of disease‐related impairment throughout the life course. British Journal of Dermatology2011;164(Suppl 1):1‐14. [MEDLINE: 21477010] ">Warren 2011</a>). Psoriasis can be itchy and painful, and application of topical therapies is time consuming and may involve mess and odour. Systemic oral therapies may have adverse effects and usually require blood‐test monitoring (<a href="./references#CD010497-bbs2-0048" title="MenterA , GriffithsCEM . Current and future management of psoriasis. Lancet2007;370(9583):272‐84. [PUBMED: 17658398] ">Menter 2007</a>). The impact of psoriasis extends beyond individuals as it may also detrimentally affect other members of the family (<a href="./references#CD010497-bbs2-0031" title="EghlilebAM , DaviesEE , FinlayAY . Psoriasis has a major secondary impact on the lives of family members and partners. British Journal of Dermatology2007;156(6):1245‐50. [MEDLINE: 17459044] ">Eghlileb 2007</a>). </p> </section> </section> <section id="CD010497-sec-0035"> <h3 class="title" id="CD010497-sec-0035">Description of the intervention</h3> <p>Oral fumaric acid esters (FAE) contain a mixture of dimethyl fumarate (DMF), thought to be the active component, and three salts of ethyl hydrogen fumarate (<a href="./references#CD010497-bbs2-0049" title="MrowietzU , ChristophersE , AltmeyerP . Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. British Journal of Dermatology1999;141(3):424‐29. [MEDLINE: 10584060] ">Mrowietz 1999</a>). Fumaderm® initial, containing 30 mg of DMF per tablet, and Fumaderm®, containing 120 mg of DMF per tablet, are commercially available. Fumaderm® has been licensed for psoriasis in Germany since 1994 (<a href="./references#CD010497-bbs2-0050" title="MrowietzU , AsadullahK . Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends in Molecular Medicine2005;11(1):43‐8. [PUBMED: 15649822] ">Mrowietz 2005</a>). At treatment initiation, gradual dose increments are recommended to improve gastrointestinal tolerance, from one tablet daily of Fumaderm® initially to a maximum of six tablets daily of Fumaderm® (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). Using the recommended dosing increments, treatment benefit is usually seen after about six to eight weeks (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). Most clinical data regarding efficacy relate to chronic plaque psoriasis. Although FAE are licensed and widely used in Germany, it was evident from the literature that they are also used in the Netherlands (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0039" title="HoefnagelJJ , ThioHB , WillemzeR , Bouwes BavinckJN . Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. British Journal of Dermatology2003;149(2):363‐9. [MEDLINE: 12932244] ">Hoefnagel 2003</a>; <a href="./references#CD010497-bbs2-0055" title="OnderdijkAJ , BalakDM , BaerveldtEM , FlorenciaEF , KantM , LamanJD , et al. Regulated genes in psoriatic skin during treatment with fumaric acid esters. British Journal of Dermatology2014;171(4):732‐41. [MEDLINE: 24852654] ">Onderdijk 2014</a>), the United Kingdom (<a href="./references#CD010497-bbs2-0036" title="HarriesMJ , ChalmersRJ , GriffithsCE . Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. British Journal of Dermatology2005;153(3):549‐51. [PUBMED: 16120141] ">Harries 2005</a>; <a href="./references#CD010497-bbs2-0061" title="SladdenMJ , OsborneJE , HutchinsonPE . Fumaric acid esters for severe psoriasis: the Leicestershire experience. British Journal of Dermatology2006;155(4):843‐4. [PUBMED: 16965442] ">Sladden 2006</a>), and Italy (<a href="./references#CD010497-bbs2-0026" title="CarboniI , DeFeliceC , DeSimoniI , SodaR , ChimentiS . Fumaric acid esters in the treatment of psoriasis: an Italian experience. Journal of Dermatological Treatment2004;15(1):23‐6. [PUBMED: 14754645] ">Carboni 2004</a>; <a href="./references#CD010497-bbs2-0043" title="KokeljF , PlozzerC , AvianA , TrevisanG . Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty‐one patients. Acta Dermatovenerologica Croatica2009;17(3):170‐5. [PUBMED: 19818215] ">Kokelj 2009</a>). The European S3 guidelines recommend measuring full blood count, liver enzymes, serum creatinine, and urine sediment before starting FAE and every four weeks during the treatment period, and pregnancy status should be checked before treatment initiation (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). </p> <section id="CD010497-sec-0036"> <h4 class="title">Adverse effects</h4> <p>Adverse effects of FAE occur in about two thirds of treated patients, particularly during the period of dose escalation (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). These are usually mild, but can lead to treatment discontinuation (<a href="./references#CD010497-bbs2-0049" title="MrowietzU , ChristophersE , AltmeyerP . Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. British Journal of Dermatology1999;141(3):424‐29. [MEDLINE: 10584060] ">Mrowietz 1999</a>). The most frequent adverse effects are gastrointestinal symptoms, including diarrhoea, increased stool frequency, nausea, and abdominal pain, as well as facial flushing (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). A decrease in the circulating lymphocyte count is seen in the majority of patients, but this does not usually require the discontinuation of treatment, and transient increases in the eosinophil count may occur (<a href="./references#CD010497-bbs2-0039" title="HoefnagelJJ , ThioHB , WillemzeR , Bouwes BavinckJN . Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. British Journal of Dermatology2003;149(2):363‐9. [MEDLINE: 12932244] ">Hoefnagel 2003</a>). Pregnancy and breastfeeding are considered absolute contraindications to fumaric acid esters because of a lack of safety data in this group (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). Severe gastrointestinal or kidney disease are also contraindications to the use of oral fumaric acid esters (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). </p> </section> </section> <section id="CD010497-sec-0037"> <h3 class="title" id="CD010497-sec-0037">How the intervention might work</h3> <p>The exact mechanisms of action of FAE are not yet fully understood, but there is increasing evidence of anti‐inflammatory effects via a number of pathways: within psoriatic plaques, dimethyl fumarate reduces the levels of several inflammatory T cell subsets (<a href="./references#CD010497-bbs2-0024" title="BovenschenHJ , LangewoutersAM , van deKerkhofPC . Dimethylfumarate for psoriasis: Pronounced effects on lesional T‐cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. American Journal of Clinical Dermatology2010;11(5):343‐50. [MEDLINE: 20553063] ">Bovenschen 2010</a>). This may be due to decreased recruitment of inflammatory cells from the blood stream (<a href="./references#CD010497-bbs2-0059" title="RubantSA , LudwigRJ , DiehlS , HardtK , KaufmannR , PfeilschifterJM , et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. Journal of Investigative Dermatology2008;128(2):326‐31. [MEDLINE: 17671516] ">Rubant 2008</a>). Fumarates also induce type II dendritic cells, which have an anti‐inflammatory effect mediated by the cytokine interleukin‐10 (<a href="./references#CD010497-bbs2-0033" title="GhoreschiK , BrückJ , KellererC , DengC , PengH , RothfussO , et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Journal of Experimental Medicine2011;208(11):2291‐303. [MEDLINE: 21987655] ">Ghoreschi 2011</a>). In addition, FAE have been shown to inhibit the formation of new blood vessels, a process that is involved in the formation of psoriatic plaques (<a href="./references#CD010497-bbs2-0032" title="García‐CaballeroM , Marí‐BeffaM , MedinaMÁ , QuesadaAR . Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?. Journal of Investigative Dermatology2011;131(6):1347‐55. [MEDLINE: 21289642] ">García‐Caballero 2011</a>; <a href="./references#CD010497-bbs2-0047" title="MeissnerM , DollM , HrgovicI , ReichenbachG , KönigV , Hailemariam‐JahnT , et al. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti‐angiogenic action. Journal of Investigative Dermatology2011;131(6):1356‐64. ">Meissner 2011</a>). </p> </section> <section id="CD010497-sec-0038"> <h3 class="title" id="CD010497-sec-0038">Why it is important to do this review</h3> <p>Current licensed oral systemic therapies, namely methotrexate, acitretin, and ciclosporin, are not effective in all of those with psoriasis and may cause adverse effects that require discontinuation of treatment. The next licensed step in treatment is expensive biologic treatment, such as anti‐TNF‐α therapy (<a href="./references#CD010497-bbs2-0063" title="SmithCH , AnsteyAV , BarkerJN , BurdenAD , ChalmersRJ , ChandlerDA , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology2009;161(5):987‐1019. [MEDLINE: 19857207] ">Smith 2009</a>). Oral fumaric acid esters are a cheaper alternative systemic therapy that are licensed in Germany, and the 2011 update of European S3 guidelines recommended FAE as first‐line systemic agents for moderate to severe psoriasis (<a href="./references#CD010497-bbs2-0052" title="NastA , BoehnckeWH , MrowietzU , OckenfelsHM , PhilippS , ReichK , et al. S3 ‐ Guidelines on the treatment of psoriasis vulgaris (English version). Update. Journal der Deutschen Dermatologischen Gesellschaft2012;10(Suppl 2):S1‐95. [MEDLINE: 22386073] ">Nast 2012</a>). However, FAE are unlicensed in many other countries, which limits their clinical use and has restricted the production of guidelines to assist patients and clinicians. For example, FAE are used to treat many individuals with psoriasis in the UK (<a href="./references#CD010497-bbs2-0036" title="HarriesMJ , ChalmersRJ , GriffithsCE . Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. British Journal of Dermatology2005;153(3):549‐51. [PUBMED: 16120141] ">Harries 2005</a>; <a href="./references#CD010497-bbs2-0061" title="SladdenMJ , OsborneJE , HutchinsonPE . Fumaric acid esters for severe psoriasis: the Leicestershire experience. British Journal of Dermatology2006;155(4):843‐4. [PUBMED: 16965442] ">Sladden 2006</a>), but no guidance exists from the National Institute for Health and Care Excellence (NICE) or the British Association of Dermatologists. This means that there is no standardisation of prescribing schedules for oral fumaric acid esters, and many dermatologists choose not to consider their use for psoriasis because of the lack of guidance. As a result, inequalities exist in psoriasis care due to patient location. This review is intended to assist in decision‐making between patients and clinicians regarding choice of systemic therapy for psoriasis. </p> <p>The plans for this review were published as a protocol 'Oral fumaric acid esters for psoriasis' (<a href="./references#CD010497-bbs2-0069" title="AtwanA , AbbottR , KellyMJ , PicklesT , BauerA , TaylorC , PiguetV , IngramJR . Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD010497] ">Atwan 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010497-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010497-sec-0039"></div> <p>To assess the effects and safety of oral fumaric acid esters for psoriasis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010497-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010497-sec-0040"></div> <section id="CD010497-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010497-sec-0042"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials, including cross‐over trials.</p> </section> <section id="CD010497-sec-0043"> <h4 class="title">Types of participants</h4> <p>We included individuals of either sex and any age and ethnicity, with a clinical diagnosis of psoriasis made by a medical practitioner. We included all subtypes of psoriasis. </p> </section> <section id="CD010497-sec-0044"> <h4 class="title">Types of interventions</h4> <p>We included all randomised controlled trials that compared oral fumaric acid esters, with or without another systemic or topical active treatment, with placebo or another active treatment: </p> <p> <ol id="CD010497-list-0001"> <li> <p>oral fumaric acid esters versus oral placebo;</p> </li> <li> <p>oral fumaric acid esters versus active treatment;</p> </li> <li> <p>oral fumaric acid esters in combination with another active treatment versus placebo; or </p> </li> <li> <p>oral fumaric acid esters in combination with another active treatment versus active treatment. </p> </li> </ol> </p> <p>We included studies that used any form of oral fumaric acid esters (FAE), including Fumaderm<i>®,</i> the main commercially available preparation. </p> </section> <section id="CD010497-sec-0045"> <h4 class="title">Types of outcome measures</h4> <section id="CD010497-sec-0046"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010497-list-0002"> <li> <p>Psoriasis Area and Severity Index (PASI) score: scale range from 0 (no disease) to 72 (maximal disease). </p> </li> <li> <p>The proportion of participants who discontinued treatment due to adverse effects that are common but sufficiently serious that the drug has had to be stopped, such as severe diarrhoea, infections, or cutaneous malignancy. </p> </li> </ol> </p> </section> <section id="CD010497-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010497-list-0003"> <li> <p>Quality of life score at follow‐up measured with a validated scale.</p> </li> <li> <p>The proportion of participants attaining PASI 50, 75, and 90, defined as a 50%, 75%, or 90% reduction in PASI score relative to the baseline PASI score immediately prior to treatment initiation. </p> </li> <li> <p>The proportion of participants experiencing any adverse effects of treatment, i.e., all nuisance side‐effects that are common, but do not mean that the drug is stopped. </p> </li> <li> <p>The proportion of participants experiencing serious adverse effects of treatment, defined as resulting in death, hospital admission, or increased duration of hospital stay. </p> </li> </ol> </p> <section id="CD010497-sec-0048"> <h6 class="title">Timing of outcome measures</h6> <p>We anticipated that the outcome measures would be of two types: those in which the treatment phase had finished and those in which the treatment phase was ongoing. We included studies of any duration, but we planned to undertake a priori subgroup analysis to investigate the influence of duration of treatment. We divided studies into short‐term treatment duration of less than 12 weeks, medium‐term duration from 12 weeks to less than 6 months, and long‐term duration of 6 months or greater. </p> </section> <section id="CD010497-sec-0049"> <h6 class="title">Economic data</h6> <p>We planned to incorporate health resource usage data, if provided, to place the clinical findings in an economic context. </p> </section> </section> </section> </section> <section id="CD010497-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD010497-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 7 May 2015:</p> <p> <ul id="CD010497-list-0004"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD010497-sec-0117">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 4, 2015) using the strategy in <a href="./appendices#CD010497-sec-0118">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD010497-sec-0119">Appendix 3</a>; </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD010497-sec-0120">Appendix 4</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD010497-sec-0121">Appendix 5</a>. </p> </li> </ul> </p> </section> <section id="CD010497-sec-0052"> <h4 class="title">Searching other resources</h4> <section id="CD010497-sec-0053"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers up to 14 May 2015 using the search terms 'Fumaric acid', 'Fumarate', and 'Fumaderm': </p> <p> <ul id="CD010497-list-0005"> <li> <p>The metaRegister of Controlled Trials (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>The EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">https://www.clinicaltrialsregister.eu/</a>). </p> </li> </ul> </p> </section> <section id="CD010497-sec-0054"> <h5 class="title">Handsearching</h5> <p>In order to identify other potential RCTs for inclusion, AA and RA handsearched the abstracts of proceedings from the following major dermatology conferences that were not already recorded in the Cochrane Skin Group Specialised Register: </p> <p> <ul id="CD010497-list-0006"> <li> <p>American Academy of Dermatology (AAD) (2008/2009);</p> </li> <li> <p>British Association of Dermatologists (BAD) (2008/2009/2010);</p> </li> <li> <p>European Academy of Dermatology and Venereology (EADV) (from 2006 to May 2013);</p> </li> <li> <p>European Society for Dermatological Research (ESDR) (2005/2006/2007/2008/2009);</p> </li> <li> <p>International Investigative Dermatology (IID) (from 2003 to May 2013); and</p> </li> <li> <p>Society for Investigative Dermatology (SID) (2007/2008/2009).</p> </li> </ul> </p> </section> <section id="CD010497-sec-0055"> <h5 class="title">References from included and excluded studies</h5> <p>We checked the reference lists of included and excluded studies for further references to relevant trials. </p> </section> <section id="CD010497-sec-0056"> <h5 class="title">Correspondence</h5> <p>We contacted by email the corresponding authors of included and excluded FAE clinical trials to check for further unpublished RCTs. We corresponded with authors where necessary to determine if a study met the criteria for inclusion and to obtain additional data where necessary. </p> </section> <section id="CD010497-sec-0057"> <h5 class="title">Adverse effects</h5> <p>From the included studies we identified, we examined data on adverse effects of the interventions. However, we did not perform a separate search for rare or delayed adverse effects. </p> </section> </section> </section> <section id="CD010497-sec-0058"> <h3 class="title" id="CD010497-sec-0058">Data collection and analysis</h3> <p>Some parts of the methods section of this review uses text that was originally published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and other Cochrane reviews co‐authored by JI and VP (predominantly, <a href="./references#CD010497-bbs2-0041" title="IngramJR , DesaiN , KaiAC , ChuaSL , WooPN , KerdelF , et al. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD010081] ">Ingram 2012</a>). </p> <section id="CD010497-sec-0059"> <h4 class="title">Selection of studies</h4> <p>Two authors (AA and RA) independently compared the titles and abstracts of the studies retrieved by the searches with the inclusion criteria. They examined the full texts of studies that potentially met the criteria, as well as the studies whose abstracts did not provide sufficient information. A third author (JI) resolved any disagreements in terms of final study selection. We recorded the reasons for exclusion of studies in the '<a href="./references#CD010497-sec-0134" title="">Characteristics of excluded studies</a>' tables. </p> </section> <section id="CD010497-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>Two authors (AA and RA) independently extracted data using a data extraction form based on the 'Checklist of items to consider in data collection or data extraction' found in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). They sought the following information from the reports of included studies: study design and methodology, participants, interventions used, reported outcomes, selection bias, performance bias, detection bias, attrition bias, reporting bias, and any other sources of bias. A third author (JI) resolved any disagreements. Two authors (AA and RA) piloted the data collection form prior to use. We entered the information collected into the '<a href="./references#CD010497-sec-0133" title="">Characteristics of included studies</a>' tables. </p> </section> <section id="CD010497-sec-0061"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (AA and RA) independently assessed the risk of bias of the included studies using The Cochrane Collaboration's 'Risk of bias' tool (<a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). They graded the risk of bias as 'low', 'high', or 'unclear' for each of the following domains:<br/> (a) random sequence generation;<br/> (b) allocation concealment;<br/> (c) blinding of participants, personnel, and outcome assessment;<br/> (d) incomplete outcome data;<br/> (e) selective outcome reporting (we checked trial databases to ensure that reported outcomes matched those prospectively listed); and<br/> (f) other sources of bias. </p> </section> <section id="CD010497-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we pooled risk ratios with 95% confidence intervals (CI). For continuous outcomes, we combined either standardised or unstandardised mean differences with 95% CI, depending on whether different scales had been used and whether change scores were to be combined with follow‐up scores. We used follow‐up scores rather than change from baseline, as recommended by The Cochrane Collaboration (<a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We planned to analyse ordinal data from short outcome scales using the methods for dichotomous data, by combining relevant adjacent categories to form a dichotomy. We planned to treat longer outcome scales as continuous data. </p> </section> <section id="CD010497-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis for our review was individual participants in the context that the intervention is a systemic treatment. We planned to permit the first phase of cross‐over trials and pool the results with those from equivalent parallel group RCTs. For cluster‐randomised trials, we planned to deflate the sample size using the design effect reported (<a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). However, we did not include any cross‐over or cluster‐randomised trials. </p> </section> <section id="CD010497-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>Whenever possible, we made contact with the original trial investigators to request any relevant unreported data. If this was unsuccessful, we planned to attempt to impute standard deviations for a small proportion of the included studies. We planned to explore the impact of missing data through sensitivity analyses. For missing dichotomous outcome data, we planned to conduct two sensitivity analyses in which we would assume all missing data to be either events or non‐events.   </p> </section> <section id="CD010497-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity using the I² statistic. We took a narrative approach and did not perform a meta‐analysis if the value of the I² statistic exceeded 75% because of considerable heterogeneity (<a href="./references#CD010497-bbs2-0054" title="O'RourkeK , DetskyAS . Meta‐analysis in medical research: strong encouragement for higher quality in individual research efforts. Journal of Clinical Epidemiology1989;42(10):1021‐4. [MEDLINE: 2809651] ">O'Rourke 1989</a>). An I² statistic of between 40% and 75% may represent substantial heterogeneity (<a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and we planned to explore the potential causes where possible for the primary outcome measures. </p> </section> <section id="CD010497-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to perform funnel plots and Egger's test for publication bias (<a href="./references#CD010497-bbs2-0030" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [MEDLINE: 9310563] ">Egger 1997</a>) if 10 or more studies contributed data; however, we did not find sufficient studies to perform a funnel plot. </p> </section> <section id="CD010497-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We dealt with the primary outcome 'PASI score' as a continuous outcome (scale 0 to 72) whereas we handled the secondary outcome components, PASI 50, 75, and 90, as dichotomous outcomes. The latter represents the proportion of participants attaining 50%, 75%, or 90% reduction in baseline PASI score, respectively. We reported pooled measures of effect with 95% confidence intervals and used a fixed‐effect model because we expected reasonable similarity across the included studies that involved the same disease and similar treatments and study populations. We planned to highlight with detailed justification if we used a random‐effects model during the analysis because of study heterogeneity. </p> </section> <section id="CD010497-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses on the following variables:</p> <p> <ul id="CD010497-list-0007"> <li> <p>treatment duration (short, medium, or long, defined as less than 12 weeks, 12 weeks to less than 6 months, or at least 6 months, respectively); and </p> </li> <li> <p>types of intervention and comparison (oral fumaric acid esters versus placebo, oral fumaric acid esters versus active treatment, etc.). </p> </li> </ul> </p> </section> <section id="CD010497-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis for studies at higher risk of bias, determined by allocation concealment and blinding of outcome assessment. We planned to conduct two sensitivity analyses in which we assumed all missing data were either events or non‐events.   </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010497-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010497-sec-0070"></div> <section id="CD010497-sec-0071"> <h3 class="title">Description of studies</h3> <p>Please see the '<a href="./references#CD010497-sec-0133" title="">Characteristics of included studies</a>' tables and the '<a href="./references#CD010497-sec-0134" title="">Characteristics of excluded studies</a>' tables. </p> <section id="CD010497-sec-0072"> <h4 class="title">Results of the search</h4> <p>The database searches identified a total of 80 records. We identified 6 additional records by handsearching and 8 by searching the trials registers (<a href="#CD010497-fig-0001">Figure 1</a>), giving a total of 78 records after the removal of duplicates and ongoing studies. We list details of the eight ongoing studies in the '<a href="./references#CD010497-sec-0135" title="">Characteristics of ongoing studies</a>' tables. Two authors independently screened the titles and abstracts yielding 11 potentially eligible reports of studies. After obtaining the full texts of these reports, we excluded five, and the remaining six were eligible for inclusion in the review. Two of the included studies were published in full reports (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>), one in a brief communication (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>), one in a letter (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), and two as abstracts (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>). We could not obtain full reports of published abstracts by contacting the authors (see 'notes' in the '<a href="./references#CD010497-sec-0133" title="">Characteristics of included studies</a>' tables of <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a> and <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>). </p> <div class="figure" id="CD010497-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010497-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010497-sec-0073"> <h4 class="title">Included studies</h4> <p>Please see the '<a href="./references#CD010497-sec-0133" title="">Characteristics of included studies</a>' tables. </p> <p>Six studies met the inclusion criteria, with a total of 544 participants.</p> <section id="CD010497-sec-0074"> <h5 class="title">Setting</h5> <p>Three of the included studies were carried out in the Netherlands (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), one in Poland (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>), and two were international multicentre studies (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>). </p> </section> <section id="CD010497-sec-0075"> <h5 class="title">Participants</h5> <p>One trial was designed to measure the treatment effect in psoriatic arthritis (PsA), but contact with the author confirmed that all participants also had psoriasis (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). We included this study to obtain data on adverse effects (AEs). All of the included studies reported participants to be adults of at least 18 years of age except <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>, which did not mention the age range of the participants. Two studies included only participants with chronic plaque psoriasis (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>); two included chronic plaque, guttate, pustular, and erythrodermic types (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>); but two studies did not report the type (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). For participants to be eligible, 1 study, <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>, required them to have a Psoriasis Area and Severity Index (PASI) score ≥ 10 at baseline; 1 study, <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>, ≥ 12; and 1 study, <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>, 16 to 24. Two studies used body surface area (BSA) to assess severity for eligibility, being at least 10% in 1 study, <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>, and more than 10% in another, <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>. One study, which was specifically designed for PsA, did not include psoriasis severity for eligibility assessment (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a> was the only study to provide details of previous psoriasis therapies, including phototherapy in 53%, conventional systemic agents in 61%, and biologic therapies in 7%. The wash‐out period was four weeks prior to randomisation. </p> </section> <section id="CD010497-sec-0076"> <h5 class="title">Design</h5> <p>Four of the included trials had a two‐arm parallel design, and of these, three compared oral fumaric acid esters (FAE) with placebo (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), and one compared FAE with methotrexate (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>). One study had a four‐group dose‐finding placebo‐controlled design (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>), and one compared FAE versus octylhydrogen fumarate plus magnesium and zinc monoethyl fumarate (MEF) versus placebo (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>). </p> </section> <section id="CD010497-sec-0077"> <h5 class="title">Interventions</h5> <p>There were some variations in the dose increments between studies. Four studies, <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>, used tablets containing a mix of dimethyl fumarate (DMF) and salts of MEF. The proportion of this mix was the same, containing 120 mg DMF and 95 mg MEF. The interventions in the other 2 studies, <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>, respectively, were BG‐12 and Panaclar™, formerly BG00012, which contained 120 mg DMF. Low‐strength tablets (containing 30 mg DMF) were given in the first 2 weeks of the intervention in <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a> and the first 3 weeks in <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a> whereas the other studies did not mention treatment initiation with low‐strength tablets (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a> increased the 120 mg DMF tablets by 1 tablet daily from week 3 to a maximum of 6 tablets daily compared with an increase of 1 tablet weekly from week 4 in <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a> to a maximum of 6 tablets daily at week 9. <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a> titrated over 7 days the maximum dose of 720 mg DMF (6 tablets). Two studies reported a gradual increase from one to six tablets daily with no further information (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). Finally, <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a> provided no information regarding dose increments in the groups who received 360 mg and 720 mg DMF daily. In the one study that compared FAE with methotrexate (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>), the methotrexate group started with an initial dose of 5 mg per week and then the dose gradually increased up to 15 mg per week orally. After 12 weeks, the study gradually reduced the dose until stopping it after week 16. </p> </section> <section id="CD010497-sec-0078"> <h5 class="title">Outcomes</h5> <p>Timing of outcome reporting was of medium‐term duration for all studies, namely at week 12 (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>) and week 16 (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). </p> <p>Not all trials reported on all outcomes prespecified in our review. The included studies reported the following outcomes: PASI score (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>); proportion of participants who discontinued treatment because of adverse effects (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>); quality of life score (<a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>); proportion of participants attaining PASI 50, PASI 75 (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>), and PASI 90 (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>); proportion of participants experiencing any AEs (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>); and proportion of participants experiencing serious AEs (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>). None of the included studies reported data on economic evaluations. </p> </section> </section> <section id="CD010497-sec-0079"> <h4 class="title">Excluded studies</h4> <p>Please see the '<a href="./references#CD010497-sec-0134" title="">Characteristics of excluded studies</a>' tables. </p> <p>We excluded five studies from the review. Four of these did not meet our prespecified type of intervention (<a href="./references#CD010497-bbs2-0007" title="BalakDM , Fallah‐AraniS , VenemaCM , NeumannHA , ThioHB . Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double‐blind placebo‐controlled trial. British Journal of Dermatology2015;172(3):754‐9. [PUBMED: 25041291] ">Balak 2015</a>; <a href="./references#CD010497-bbs2-0008" title="FriedrichM , SterryW , KleinA , RückertR , DöckeWD , AsadullahK . Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. Acta Dermato‐Venereologica2001;81(6):429‐30. [PUBMED: 11859949] ">Friedrich 2001</a>; <a href="./references#CD010497-bbs2-0009" title="GollnickH , AltmeyerP , KaufmannR , RingJ , ChristophersE , PavelS , et al. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology2002;205(1):46‐53. [PUBMED: 12145434] ">Gollnick 2002</a>; <a href="./references#CD010497-bbs2-0011" title="NieboerC , deHoopD , LangendijkPN , vanLoenenAC , GubbelsJ . Fumaric acid therapy in psoriasis: a double‐blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica1990;181(1):33‐7. [PUBMED: 2394301] ">Nieboer 1990</a>), and one did not have evidence of randomisation (<a href="./references#CD010497-bbs2-0010" title="NieboerC , deHoopD , vanLoenenAC , LangendijkPNJ , vanDijkE . Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis. Journal of the American Academy of Dermatology1989;20(4):601‐8. [PUBMED: 2654206] ">Nieboer 1989</a>). </p> </section> </section> <section id="CD010497-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>We provide details of the 'Risk of bias' assessment in the 'Risk of bias' tables (see the '<a href="./references#CD010497-sec-0133" title="">Characteristics of included studies</a>' tables). Overall, there was insufficient reporting in most of the included studies to permit judgement of 'low risk' or 'high risk' (<a href="#CD010497-fig-0002">Figure 2</a>; <a href="#CD010497-fig-0003">Figure 3</a>). One reason is the publication type of some included studies, which included two abstracts (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>), one letter (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), and one brief communication (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>). The fact that some studies were about 20 years old may also be a possible factor for insufficient reporting (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). </p> <div class="figure" id="CD010497-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD010497-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010497-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD010497-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010497-sec-0081"> <h4 class="title">Allocation</h4> <p>Only one study, <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>, reported adequate sequence generation and allocation concealment. The other studies did not report the method of sequence generation or allocation concealment. </p> </section> <section id="CD010497-sec-0082"> <h4 class="title">Blinding</h4> <p>Five of the six included studies were described as double‐blind (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). Blinding of participants and personnel (performance bias) was of unclear risk in four of these studies and high risk in one (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>). Blinding of outcome assessment (detection bias) was of low risk in one study (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), high risk in one (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>), and unclear risk in the remaining three double‐blinded studies (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>). The sixth study included in our review, <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>, had an open label design, so performance and detection biases were of high risk. </p> </section> <section id="CD010497-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>Two studies had low risk of attrition bias (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). We noted unclear risk of attrition bias in the remaining four studies (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>). </p> </section> <section id="CD010497-sec-0084"> <h4 class="title">Selective reporting</h4> <p>The protocol of one study was prospectively registered (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>). We noted slight variations between the registered protocol and published report, but contact with the author confirmed that the relevant ethics committee had approved some minor changes after registering the protocol. We observed high risk of selective reporting in one study that mentioned PASI, Physician's Clinical Global Impression, Patient's Global Assessment, and Skindex‐29 in the methodology, but only reported PASI in the results of the published abstract (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>). The risk was unclear in other studies (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). We did not perform funnel plots and Egger's test to assess publication bias because fewer than 10 studies contributed data in our review. </p> </section> <section id="CD010497-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>The risk of other potential sources of bias was low in one study (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>), unclear in four studies (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), and high in one study (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>). </p> </section> </section> <section id="CD010497-sec-0086"> <h3 class="title" id="CD010497-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD010497-tbl-0001"><b>Summary of findings for the main comparison</b> FAE compared with placebo for psoriasis</a>; <a href="./full#CD010497-tbl-0002"><b>Summary of findings 2</b> FAE compared with MTX for psoriasis</a> </p> <p>All of the included studies had a medium duration (12 weeks to less than 6 months), so we did not perform a subgroup analysis for different treatment durations. We did not perform sensitivity analysis because the risk of bias in the included studies was mostly unclear. Five studies compared oral fumaric acid esters (FAE) with placebo, and one study compared FAE with methotrexate. We discuss these two comparisons individually in our review and summarise them in two 'Summary of findings' ('SoF') tables (see <a href="./full#CD010497-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010497-tbl-0002">summary of findings Table 2</a>). </p> <p>We have mainly used a narrative approach to present the effects of FAE in the treatment of psoriasis because of a lack of opportunities for meta‐analysis. We combined data from 2 reports comparing FAE with placebo in a meta‐analysis for one of the secondary outcomes, PASI 50 (see <a href="./references#CD010497-sec-0115" title="">Data and analyses</a>). Of note, reduction in PASI score is a beneficial outcome, while PASI 50 refers to the proportion of participants achieving a 50% decrease in baseline PASI, so a higher PASI 50 represents greater treatment success. None of the included studies reported data on economic evaluations, so this was not possible to measure in our review. </p> <section id="CD010497-sec-0087"> <h4 class="title">Comparison of oral fumaric acid esters with placebo</h4> <p>Five studies compared FAE with placebo for the treatment of psoriasis (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), one of which was designed to measure the treatment effect in psoriatic arthritis (PsA) where all participants also had psoriasis (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). Three studies used a mixture of dimethyl fumarate (DMF) plus monoethyl fumarate (MEF) in enteric‐coated tablets as an intervention (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>) whereas the other two studies used DMF alone (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>). </p> <p>The following studies reported our prespecified outcomes: <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a> (PASI score); <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a> (proportion of participants who discontinued treatment because of adverse effects); <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a> (quality of life (QoL) score); <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a> (proportion of participants attaining PASI 50 and PASI 75); and <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a> (proportion of participants experiencing common nuisance adverse effects). The quality of the evidence was 'moderate' for proportion of participants experiencing any common nuisance adverse effects; 'low' for PASI score, quality of life, and proportion of participants attaining PASI 50 and PASI 75; and 'very low' for proportion of participants who experienced adverse effects that led to treatment discontinuation (see <a href="./full#CD010497-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The included studies did not report serious adverse effects, and it was unclear whether any of the adverse effects leading to treatment discontinuation were serious. A meta‐analysis of results from 2 studies was possible for PASI 50 and PASI 75 data; however, we reported only the PASI 50 meta‐analysis results because of significant heterogeneity for the PASI 75 data. Meta‐analyses were not possible for all other outcomes, so we did not report these in a narrative manner. </p> <section id="CD010497-sec-0088"> <h5 class="title">Primary outcomes</h5> <section id="CD010497-sec-0089"> <h6 class="title">PASI score</h6> <p><a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a> reported a reduction of PASI score from a mean of 21.57 at baseline to 10.77 after 16 weeks of FAE treatment whereas in the placebo group, it remained constant. The study reported the difference between groups at week 16 to be statistically significant (P &lt; 0.0001). The text did not report mean PASI scores at baseline and week 16 for the placebo group. We attempted to obtain these values from the line graph provided in the study report by using a magnified Excel worksheet to read the values. This highlighted differences compared with the text of the report for the PASI scores relating to the FAE group. Attempts to contact the authors to seek clarification were unsuccessful, so on balance, we decided that the text values for the FAE group PASI scores were more likely to be accurate and avoided calculation of a mean difference with confidence intervals to prevent introduction of potential error into our review. </p> <p><a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>, which compared 3 doses of FAE (120 mg, 360 mg, 720 mg) with placebo, reported the median percentage reduction from baseline PASI as 31%, 52%, 71%, and 6%, respectively, after 12 weeks. The study reported this to be statistically significant for the 360 mg and 720 mg dose groups compared with placebo (P &lt; 0.001). The paper did not report mean PASI scores at baseline and follow‐up. </p> <p>Similarly, <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a> reported the median PASI score at week 16 in 2 groups that received either FAE (n = 105) or placebo (n = 70). The study reported the median score to be lower with FAE at 5.8 compared with 14.2 with placebo (P &lt; 0.001), which represented a 67.8% and 10.2% reduction, respectively. The study also did not report mean PASI scores at baseline and follow‐up, but reported an effect size of 7.4 (95% confidence interval (CI) 5.40 to 9.40). </p> <p>The other two studies comparing FAE with placebo did not include a PASI score and instead measured the disease severity by estimating the body surface area (BSA) involved (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>), "scoring the degree of infiltration and scaling of the plaques from 0 (no infiltration or scaling) to 8 (very severe infiltration or scaling)" (<a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>), or scoring the degree of erythema and scaling on a scale range from 0 to 8 (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). </p> </section> <section id="CD010497-sec-0090"> <h6 class="title">Proportion of participants who discontinued treatment due to adverse effects</h6> <p>Only one study accounted for the number of participants who dropped out solely due to adverse effects (AE) (<a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>). In this 16‐week study, 2 participants from the FAE group (n = 13) withdrew from the study (1 after 6 weeks because of diarrhoea that could not be controlled by lowering the treatment dose and 1 after 12 weeks because of proteinuria and elevated serum creatinine levels, which were reversible several weeks after treatment discontinuation), compared with no withdrawals from the placebo group (n = 14) (risk ratio (RR) 5.36, 95% CI 0.28 to 102.12; 1 study, 27 participants; very low‐quality evidence) (<a href="./references#CD010497-fig-0004" title="">Analysis 1.1</a>). However, these findings were uncertain because of indirectness and a very wide confidence interval. </p> <p><a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a> reported that of the 39 participants equally randomised to receive FAE (DMF plus MEF), octylhydrogen fumarate plus magnesium and zinc salts of MEF, or placebo, 34 completed the study. The number of participants who completed the study in each group showed one dropout from the FAE group, three from the octylhydrogen fumarate plus magnesium and zinc salts of MEF group, and one from the placebo group, but the reasons were unclear. The study reported that all 13 participants in the FAE group had diarrhoea, and 1 became ill as a result of renal insufficiency. </p> <p>In another study (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>), the number of dropouts due to AEs alone was not possible to establish because FAE was terminated prematurely in 19 (38.8%) participants because of AEs (n = 4), deterioration (n = 5), and several reasons including "no change, increase in the extent and side effects" (n = 10). In comparison, 29 (58.0%) in the placebo group withdrew because of worsening (n = 22), gastrointestinal disturbances (n = 1), and general dissatisfaction with treatment outcome (n = 6). </p> <p>The two studies published in abstracts, <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>, did not report the number of participants who completed the study and whether there were any dropouts due to AEs. </p> </section> </section> <section id="CD010497-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD010497-sec-0092"> <h6 class="title">Quality of life (QoL) score</h6> <p>One study, <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>, reported quality of life assessment using Skindex‐29 (range = 0 to 100; higher scores indicated a lower level of QoL). Mean Skindex‐29 scores reduced from 54.7 at baseline to 27.0 at week 16 in the FAE group (n = 105) compared with a reduction from 54.0 to 51.1 in the placebo group (n = 70). This reduction correlated to a 47% improvement in quality of life with FAE with a reported between‐group difference of ‐19.27 (P &lt; 0.001). </p> </section> <section id="CD010497-sec-0093"> <h6 class="title">Proportion of participants attaining PASI 50, 75, and 90</h6> <p>The included studies reported PASI 50 and PASI 75 (<a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a>; <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>). The number of participants who achieved PASI 50 was greater with FAE compared with placebo (RR 4.55, 95% CI 2.80 to 7.40; P &lt; 0.00001; I² statistic = 0%; 2 studies, 247 participants; low‐quality evidence) (<a href="./references#CD010497-fig-0005" title="">Analysis 1.2</a>). More participants on FAE therapy also attained PASI 75, but due to substantial heterogeneity (I² statistic = 77%) between these 2 studies, we could not combine them. </p> <p><a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a> reported the change of PASI by calculating the remission index. This was categorised into bands different from the standard PASI 50, 75, and 90 as follows: &gt; 95%, 70% to 95%, 30% to 69%, &lt; 30%, 0%, and &lt; 0%; hence, we could not integrate these into the above calculations. </p> <p>The remaining two studies, <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>, did not use PASI for severity assessment. </p> </section> <section id="CD010497-sec-0094"> <h6 class="title">Proportion of participants experiencing any adverse effects of treatment</h6> <p>Based on one study (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>), the number of participants experiencing AEs was higher with FAE compared with placebo (RR 4.72, 95% CI 2.45 to 9.08; 1 study, 99 participants; moderate‐quality evidence) (<a href="./references#CD010497-fig-0006" title="">Analysis 1.3</a>). The authors also stated the total number of times that an AE was reported, including multiple reports from the same participant. These included stomach ache or cramps (35 times versus twice), diarrhoea (27 times versus twice), flushing (21 times versus none), skin burning (twice versus once), and itching (once versus none). Laboratory findings showed no change in haemoglobin and erythrocyte count, with no differences between groups or within groups. The study noted a mild decrease in leukocytes at week eight in both groups with no changes thereafter. Although between‐group analysis at week 16 showed no significant difference, within‐group comparison showed a statistically significant decrease in the FAE group (P = 0.0163). The eosinophil count was unchanged in the placebo group, but increased in the FAE group from 2% (day 0) to 3.4% at 4 weeks (P &lt; 0.05), with a further insignificant increase to 4.7% at week 12. Eosinophilia at 28% was noted in 1 participant (unknown time point). Lymphocyte count was unchanged in the placebo group whereas the study reported a non‐significant reduction in the FAE group between baseline and week 16. No significant changes were noted in platelet count or levels of bilirubin, urea, creatinine, glucose, alkaline phosphatase, transaminases, gamma glutamyltransferase (GGT), cholesterol, triglycerides, urinalysis, and creatinine clearance in either group. </p> <p>One study, <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>, reported diarrhoea, nausea, headache, and flushing as the most common side‐effects in both FAE and placebo groups, but provided no numerical values to compute the difference. The study reported these adverse effects to be temporary in most participants and improved after reducing the dose or altering the dietary regimen (no further details). Within‐group analysis showed a statistically significant reduction in the erythrocyte sedimentation rate (ESR) (P = 0.007) and alkaline phosphatase (P = 0.005) with FAE whereas haemoglobin, leucocytes, lymphocytes, platelets, and serum creatinine did not significantly change in either group. Comparison between the 2 groups showed statistically significant lower ESR in the FAE group (P = 0.02), lower leucocyte levels (P = 0.02), lower platelet levels (P = 0.02), and lower alkaline phosphatase activity (P = 0.005)<i>.</i> However, as participants had psoriatic arthritis, the effect on these markers may not have been representative for individuals with psoriasis alone. </p> <p>In <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>, 3 groups were treated with FAE (DMF plus several types of MEF) (group 1 = 13), octylhydrogen fumarate plus magnesium MEF (5 mg) and zinc MEF (3 mg) (group 2 = 13), or placebo (group 3 = 13). Group 1 reported the most common adverse effects as flushing (n = 12), diarrhoea (n = 13), fatigue (n = 7), and nausea (n = 6). One participant showed a rise of serum creatinine up to 238 umol/L and reduction of creatinine clearance rate by 51%; this was reported to be reversible. Twelve participants in group 2 developed diarrhoea as a main adverse effect. Group one (n = eight) and group two (n = four) reported transient elevation of liver enzymes. Other abnormalities observed in group one were transient eosinophilia (five participants) and lymphopenia (four). The study provided no information about dropouts in the placebo group, and it was unclear which of the mentioned AEs led to treatment discontinuation in each group. </p> <p><a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a> did not report the number of participants experiencing AEs. The abstract reported that 58% of FAE‐treated participants compared with 23% of those receiving placebo had gastrointestinal AEs. Eighty‐two per cent of these were classified as mild to moderate in severity (unclear if some, or all, of the remaining 18% dropped out because of severe symptoms). Forty‐two per cent of participants reported flushing in the FAE group compared with 9% in the placebo group. There were no clinically relevant trends to abnormal values in haematology, chemistry, renal, or hepatic function studies. The study reported the adverse events to be generally mild to moderate in severity and transient. </p> <p><a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a> reported that the most common AEs were flushing, minor plasma elevations of the liver enzyme alanine aminotransferase (ALT), common colds, and a low rate of gastrointestinal events. (There were no numerical values to show if this was dose‐dependant or severe enough to cause treatment discontinuation.) </p> </section> <section id="CD010497-sec-0095"> <h6 class="title">Proportion of participants experiencing serious adverse effects</h6> <p>None of the studies reported whether any of the adverse events that led to treatment discontinuation were serious. </p> </section> </section> </section> <section id="CD010497-sec-0096"> <h4 class="title">Comparison of FAE with methotrexate</h4> <p>Only one study with an open label design compared FAE with methotrexate (MTX) (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>). Reported outcomes included PASI score; proportion of participants who discontinued treatment because of adverse effects; proportion of participants who achieved PASI 50, 75, and 90; and proportion of participants experiencing common nuisance and serious adverse effects. We graded the quality of the evidence for these outcomes as 'very low' (see <a href="./full#CD010497-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD010497-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD010497-sec-0098"> <h6 class="title">PASI score</h6> <p>After 12 weeks of treatment, the mean PASI score decreased from 14.5 (standard deviation (SD) 3.0) at baseline to 6.7 (SD 4.5) in the 25 participants treated with MTX compared with a reduction from 18.1 (SD 7.0) at baseline to 10.5 (SD 6.7) in the 26 participants treated with FAE. After adjustment for baseline values, the absolute difference (FAE minus MTX) at 12 weeks was 1.4 (95% CI ‐2.0 to 4.7; P = 0.417). However, when we compared the PASI scores at follow‐up (week 12), as recommended by The Cochrane Collaboration, this difference was in favour of MTX (mean difference (MD) 3.80, 95% CI 0.68 to 6.92; 1 study, 51 participants; very low‐quality evidence) (<a href="./references#CD010497-fig-0007" title="">Analysis 2.1</a>). </p> </section> <section id="CD010497-sec-0099"> <h6 class="title">Proportion of participants who discontinued treatment due to adverse effects</h6> <p>Five of the 25 participants treated with MTX dropped out due to AEs (4 because of elevated liver enzymes and 1 because of recurrent angina) compared with 1 dropout in the 26 treated with FAE because of diarrhoea. This difference was not significant (RR 0.19, 95% CI 0.02 to 1.53; 1 study, 51 participants; very low‐quality evidence) (<a href="./references#CD010497-fig-0008" title="">Analysis 2.2</a>). The study reported the elevated liver enzymes to be transient and normalised four to eight weeks after treatment cessation. </p> </section> </section> <section id="CD010497-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD010497-sec-0101"> <h6 class="title">Quality of life (QoL) score</h6> <p>Quality of life was not assessed in this study.</p> </section> <section id="CD010497-sec-0102"> <h6 class="title">Proportion of participants attaining PASI 50, 75, and 90</h6> <p>There was no significant difference in the number of participants who attained PASI 50 (<a href="./references#CD010497-fig-0009" title="">Analysis 2.3</a>), 75 (<a href="./references#CD010497-fig-0010" title="">Analysis 2.4</a>), and 90 (<a href="./references#CD010497-fig-0011" title="">Analysis 2.5</a>) in the 2 groups. Eleven of the 26 participants treated with FAE and 15 of the 25 treated with MTX achieved PASI 50 after 12 weeks (RR 0.71, 95% CI 0.41 to 1.22; 1 study, 51 participants; very low‐quality evidence). Five participants who received FAE attained PASI 75 compared with 6 in the MTX group (RR 0.80, 95% CI 0.28 to 2.29; 1 study, 51 participants; very low‐quality evidence), while PASI 90 was observed in 1 participant in the FAE group and 2 in the MTX group (RR 0.48, 95% CI 0.05 to 4.98; 1 study, 51 participants; very low‐quality evidence). </p> </section> <section id="CD010497-sec-0103"> <h6 class="title">Proportion of participants experiencing any adverse effects of treatment</h6> <p>The number of participants experiencing adverse effects of treatments was not significantly different between the two groups. Whereas 24 of the 27 participants in the FAE group reported AEs, all 27 in the MTX group experienced AEs (RR 0.89, 95% CI 0.77 to 1.03; 1 study, 54 participants; very low‐quality evidence) (<a href="./references#CD010497-fig-0012" title="">Analysis 2.6</a>). However, more participants experienced flushing in the FAE group (13 versus 2) (RR 6.50, 95% CI 1.62 to 26.09). Participants in the FAE group reported influenza‐like symptoms less commonly than those in the MTX group (1 versus 7), but this difference was not significant (RR 0.14, 95% CI 0.02 to 1.08). There was no significant difference in reported laboratory findings between the two groups. Transient elevation of liver enzymes (100% to 200% of the values at screening visit) was observed in 3 of the 27 participants in the FAE group and 8 of the 27 participants in the MTX group (RR 0.38, 95% CI 0.11 to 1.26). There was transient eosinophilia (maximum measured level 1.55 x 10⁹ L⁻¹) in 5 participants in the FAE group compared with none of those in the MTX group (RR 11.00, 95% CI 0.64 to 189.65) and transient leucocytopenia (2.1 x 10⁹ L⁻¹) in 1 participant in the FAE group compared with none in the MTX group (RR 3.00, 95% CI 0.13 to 70.53), and there were similar findings for lymphocytopenia. Transient thrombocytosis (with a maximum level of 422 x 10⁹ L⁻¹) was not noted in the FAE group compared with 1 occurrence in the MTX group (RR 0.33, 95% CI 0.01 to 7.84), and finally, an equal number of 8 participants from each group showed transient proteinuria (RR 1.00, 95% CI 0.44 to 2.28). </p> </section> <section id="CD010497-sec-0104"> <h6 class="title">Proportion of participants experiencing serious adverse effects</h6> <p>This study reported that none of the participants experienced any serious or irreversible adverse effects. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010497-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010497-sec-0105"></div> <section id="CD010497-sec-0106"> <h3 class="title" id="CD010497-sec-0106">Summary of main results</h3> <p>The aim of this review was to provide the best available evidence on the efficacy and safety of oral fumaric acid esters (FAE) for the treatment of psoriasis. We included 6 randomised controlled trials (RCTs), with a total of 544 participants, in this review. Five of these studies compared FAE with placebo. We could not pool data from these studies in meta‐analyses because of variations in reported outcomes and insufficient reporting; the only exception was for the Psoriasis Area and Severity Index (PASI) 50, which 2 studies reported. The meta‐analysis included 247 participants and demonstrated a combined PASI 50 of 64% for those given FAE compared with a PASI 50 of 14% for those on placebo, representing a number needed to treat to benefit (NNTB) of 2. This favourable NNTB result should be viewed in the context that PASI 50 has been superseded by PASI 75 as the standard psoriasis outcome measure (<a href="./references#CD010497-bbs2-0063" title="SmithCH , AnsteyAV , BarkerJN , BurdenAD , ChalmersRJ , ChandlerDA , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology2009;161(5):987‐1019. [MEDLINE: 19857207] ">Smith 2009</a>), and some have argued that in the era of biologic therapies, PASI 90 should be the treatment goal. Three of the studies reported statistically significant reduction of PASI scores with FAE when compared with placebo, but we could not evaluate the mean difference. We obtained the dropout rate due to adverse effects (AEs) from one study with uncertain findings due to indirectness and a very wide confidence interval. Combining data on PASI 50 from 2 studies showed significant benefit in favour of FAE compared with placebo; unfortunately, PASI 75 data showed significant heterogeneity (I² statistic = 77%), so we did not combine these studies. One report indicated 47% improvement in quality of life (QoL) with FAE with a reported between‐group difference of ‐19.27 (P &lt; 0.001). Another study reported a significantly higher number of participants experiencing common AEs with FAE, mostly stomach‐ache or cramps, diarrhoea, flushing, and eosinophilia. </p> <p>One of the included studies showed that the effect of FAE on PASI score was comparable to methotrexate (MTX) in terms of change from baseline. However, comparing PASI scores between groups at the endpoint showed favour of MTX due to a disparity in baseline disease severity between the two groups. The number of participants achieving PASI 50, 75, and 90 was not significantly different, and dropout rates because of AEs were similar. The overall number of participants experiencing common nuisance AEs (not leading to treatment discontinuation) was not significantly different between the two groups; however, flushing was more likely for FAE compared with MTX. No serious AEs were observed in any of the participants, and unfortunately, the included studies did not assess the effects on participants' QoL. </p> </section> <section id="CD010497-sec-0107"> <h3 class="title" id="CD010497-sec-0107">Overall completeness and applicability of evidence</h3> <p>The small number of included studies and insufficient reporting of outcomes were major limitations to address the objectives of this review. Some studies included participants with various types of psoriasis, but the outcomes reported did not indicate whether the response to FAE varied between these different types. The majority of studies comparing FAE with placebo did not report the number of participants who completed the study or dropped out because of AEs. We were also unable to draw conclusions regarding whether the variations in dose increments had an impact on the magnitude of treatment effect or risk of AEs. More recently, the European S3 psoriasis guidelines has standardised the schedule of dose increments (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). We were unable to establish if the use of dimethyl fumarate (DMF) alone has a similar efficacy and safety profile as the mixture of DMF plus monoethyl fumarate (MEF). Methotrexate (MTX) is used as a first‐line oral treatment for psoriasis in many countries, so it was useful to compare MTX with FAE in one of the included studies. However, the maximum dose of MTX used in this study may have been suboptimal as higher doses can be administered in routine clinical practice and also the time of assessment at 12 weeks might have been too brief to evaluate true efficacy. Although the study reported no significant difference in the percentages of participants who achieved PASI 75 and PASI 90 in week 16 after oral treatment was stopped, it must be noted that the dose of MTX was reduced gradually from week 12. So it is unclear if this difference would remain insignificant if MTX was continued at the same dose. Unfortunately, none of the included studies reported long‐term follow‐up data; therefore, we could not establish the long‐term efficacy and safety of FAE from the included trials. Also, none of the included studies reported data on economic evaluations, so this was not possible to measure in our review. </p> </section> <section id="CD010497-sec-0108"> <h3 class="title" id="CD010497-sec-0108">Quality of the evidence</h3> <p>We obtained data presented in this review from six reports, including two abstracts, one brief communication, and one letter. Incompletely reported studies have their limitations; however, we felt it was important to include them in this review because of the overall lack of eligible RCTs. These 6 studies included 544 adult participants in total. Five studies compared FAE with placebo in a double‐blind fashion, and one compared FAE with an active comparator, methotrexate, in an open label study. Four studies reported PASI score as a primary outcome, which they presented in different ways as mean scores at baseline and endpoint, percentage of median reduction from baseline, and median scores at endpoint. Insufficient reporting did not allow us to conduct multiple meta‐analyses in order to draw robust conclusions. Overall, the evidence for reported outcomes was of low quality in studies that compared FAE with placebo and very low quality in those that compared FAE with methotrexate (see <a href="./full#CD010497-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010497-tbl-0002">summary of findings Table 2</a>). It is worth noting that some of the included studies were conducted before the requirement for trial registration. Also, we were unable to perform funnel plot or Egger's test to assess the risk of publication bias because of the small number of included studies. </p> </section> <section id="CD010497-sec-0109"> <h3 class="title" id="CD010497-sec-0109">Potential biases in the review process</h3> <p>To our knowledge, we have identified all of the studies related to this review. In addition to electronic searches performed by the Trials search co‐ordinator in the Cochrane Skin Group (CSG), one author (AA) searched other resources (including trial registers, handsearching, and grey literature). To minimise the possibility of missing reports, two authors (AA, JRI) independently screened the titles and abstracts to identify potential relevant studies. Following this, two authors (AA, RA) read the full papers of identified studies and extracted data from the eligible ones using the same data extraction form. The two authors resolved discrepancies in 'Risk of bias' assessment between them or with the judgment of a third author (JRI) if they reached no initial agreement. When queries about included studies emerged, one author (AA) contacted study authors (please see 'notes' in the '<a href="./references#CD010497-sec-0133" title="">Characteristics of included studies</a>' tables for details). In some cases, we did not receive replies, in part due to the length of time that had elapsed since the studies were performed. We regularly sought and followed advice from the CSG throughout the review process. It is worth noting that the use of different cut‐off points for the PASI score (i.e., PASI 50, 75, and 90) is likely to be highly correlated with the absolute PASI score and therefore an update of this review should consider selecting only one of these outcomes. We planned to avoid meta‐analysis if the value of the I² statistic exceeded 75%, so did not combine PASI 75 data for <a href="./references#CD010497-bbs2-0003" title="LangnerA , RoszkiewiczJ , BaranE , PlacekW . Results of a phase II study of a novel oral fumarate, BG‐12, in the treatment of severe psoriasis (Abstract P075). European Congress on Psoriasis 2004. Journal of the European Academy of Dermatology &amp; Venereology2004;18(6):798. ">Langner 2004</a> and <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>, although we concede that this is a somewhat arbitrary threshold for assessing heterogeneity, which may depend on several factors (section 9.5.2: <a href="./references#CD010497-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010497-sec-0110"> <h3 class="title" id="CD010497-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>We identified one systematic review for treatments of severe psoriasis including FAE (<a href="./references#CD010497-bbs2-0034" title="GriffithsCE , ClarkCM , ChalmersRJ , Li Wan PoA , WilliamsHC . A systematic review of treatments for severe psoriasis. Health Technology Assessment2000;4(40):1‐125. [DOI: 10.3310/hta4400; MEDLINE: 11207450] ">Griffiths 2000</a>). <a href="./references#CD010497-bbs2-0034" title="GriffithsCE , ClarkCM , ChalmersRJ , Li Wan PoA , WilliamsHC . A systematic review of treatments for severe psoriasis. Health Technology Assessment2000;4(40):1‐125. [DOI: 10.3310/hta4400; MEDLINE: 11207450] ">Griffiths 2000</a> included five studies, two of which we excluded from our review (<a href="./references#CD010497-bbs2-0010" title="NieboerC , deHoopD , vanLoenenAC , LangendijkPNJ , vanDijkE . Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis. Journal of the American Academy of Dermatology1989;20(4):601‐8. [PUBMED: 2654206] ">Nieboer 1989</a>; <a href="./references#CD010497-bbs2-0011" title="NieboerC , deHoopD , LangendijkPN , vanLoenenAC , GubbelsJ . Fumaric acid therapy in psoriasis: a double‐blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica1990;181(1):33‐7. [PUBMED: 2394301] ">Nieboer 1990</a>) ‐ please see the '<a href="./references#CD010497-sec-0134" title="">Characteristics of excluded studies</a>' studies for the reasons for exclusion. <a href="./references#CD010497-bbs2-0034" title="GriffithsCE , ClarkCM , ChalmersRJ , Li Wan PoA , WilliamsHC . A systematic review of treatments for severe psoriasis. Health Technology Assessment2000;4(40):1‐125. [DOI: 10.3310/hta4400; MEDLINE: 11207450] ">Griffiths 2000</a> excluded <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a> as it was essentially designed for psoriatic arthritis rather than psoriasis. However, our contact with the author confirmed that all participants also had psoriasis and we therefore included this study in our review, mainly to obtain adverse effects data. </p> <p>The <a href="./references#CD010497-bbs2-0034" title="GriffithsCE , ClarkCM , ChalmersRJ , Li Wan PoA , WilliamsHC . A systematic review of treatments for severe psoriasis. Health Technology Assessment2000;4(40):1‐125. [DOI: 10.3310/hta4400; MEDLINE: 11207450] ">Griffiths 2000</a> review dealt with variations in reporting of average PASI scores by dichotomising the response in terms of 'successful' or 'unsuccessful' treatment in order to report the treatment success rate as a risk difference (RD). This permitted a meta‐analysis from which the authors of the <a href="./references#CD010497-bbs2-0034" title="GriffithsCE , ClarkCM , ChalmersRJ , Li Wan PoA , WilliamsHC . A systematic review of treatments for severe psoriasis. Health Technology Assessment2000;4(40):1‐125. [DOI: 10.3310/hta4400; MEDLINE: 11207450] ">Griffiths 2000</a> review concluded that FAE was superior to placebo with a pooled RD value of 0.47 (95% confidence interval (CI) 0.33 to 0.61) (combined results of <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0005" title="Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy for psoriasis: A randomized, double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1990;22(2 Pt 1):311‐312. [PUBMED: 2312814] Nugteren‐HuyingWM , van derSchroeffJG , HermansJ , SuurmondD . Fumaric acid therapy in psoriasis; a double‐blind, placebo‐controlled study [Fumaarzuurtherapie tegen psoriasis; een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1990;134(49):2387‐91. [PUBMED: 2263264] ">Nugteren‐Huying 1990</a>). <a href="./references#CD010497-bbs2-0034" title="GriffithsCE , ClarkCM , ChalmersRJ , Li Wan PoA , WilliamsHC . A systematic review of treatments for severe psoriasis. Health Technology Assessment2000;4(40):1‐125. [DOI: 10.3310/hta4400; MEDLINE: 11207450] ">Griffiths 2000</a> performed no meta‐analyses regarding adverse effects or other outcomes specified in our review. </p> <p><a href="./references#CD010497-bbs2-0051" title="MustafaAA , Al‐HoqailIA . Biologic systemic therapy for moderate‐to‐severe psoriasis: A review. Journal of Taibah University Medical Sciences2013;8(3):142‐50. [DOI: 10.1016/j.jtumed.2013.09.001] ">Mustafa 2013</a> performed a systematic review that included 21 RCTs reporting efficacy of systemic treatments for moderate to severe psoriasis. The <a href="./references#CD010497-bbs2-0051" title="MustafaAA , Al‐HoqailIA . Biologic systemic therapy for moderate‐to‐severe psoriasis: A review. Journal of Taibah University Medical Sciences2013;8(3):142‐50. [DOI: 10.1016/j.jtumed.2013.09.001] ">Mustafa 2013</a> review included 16 RCTs in meta‐analyses where risk difference (RD) was reported to measure treatment effect whereas tolerability was assessed from rates of withdrawal and adverse effects. Although the review stated that it would study systemic treatments approved for moderate to severe psoriasis, it only reported results for biologics. The abstract of <a href="./references#CD010497-bbs2-0051" title="MustafaAA , Al‐HoqailIA . Biologic systemic therapy for moderate‐to‐severe psoriasis: A review. Journal of Taibah University Medical Sciences2013;8(3):142‐50. [DOI: 10.1016/j.jtumed.2013.09.001] ">Mustafa 2013</a> mentioned, 'Rates of withdrawals due to adverse events were highest for methotrexate and oral fumaric acid esters', but the paper provided no other information. We contacted the author on 9 July 2014 for clarifications and had received no response at the point of submitting this review. </p> <p>More recently, <a href="./references#CD010497-bbs2-0060" title="SchmittJ , RosumeckS , ThomaschewskiG , SporbeckB , HaufeE , NastA . Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials. British Journal of Dermatology2014;170(2):274‐303. [MEDLINE: 24131260] ">Schmitt 2014</a> conducted a systematic review to measure the efficacy and safety of systemic treatments, including biologics and conventional systemic therapies, for moderate to severe psoriasis. The review included only fully published RCTs and excluded review papers, letters, and abstracts. With regard to FAE, <a href="./references#CD010497-bbs2-0060" title="SchmittJ , RosumeckS , ThomaschewskiG , SporbeckB , HaufeE , NastA . Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials. British Journal of Dermatology2014;170(2):274‐303. [MEDLINE: 24131260] ">Schmitt 2014</a> included two studies (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>). The review found that FAE is superior to placebo based on mean PASI change (<a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>) and has similar efficacy to MTX (absolute risk difference 0.05, 95% CI ‐0.18 to 0.27) (<a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>), in agreement with the findings of our Cochrane review, which calculated risk ratios. In keeping with our review, <a href="./references#CD010497-bbs2-0060" title="SchmittJ , RosumeckS , ThomaschewskiG , SporbeckB , HaufeE , NastA . Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials. British Journal of Dermatology2014;170(2):274‐303. [MEDLINE: 24131260] ">Schmitt 2014</a> reported that the rates of adverse effects and withdrawals did not differ between FAE and MTX, but did not undertake statistical analysis. </p> <p>A systematic review by <a href="./references#CD010497-bbs2-0027" title="CeglowskaU , WlodarczykA , SlomkaM . Clinical effectiveness of fumaric acid esters (Fumaderm) in psoriasis: A systematic review of literature. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands, Nov 2014:PSS6. ">Ceglowska 2014</a> in a conference proceeding reported clinical effectiveness of FAE for psoriasis and psoriatic arthritis. This review included three studies, <a href="./references#CD010497-bbs2-0001" title="AltmeyerPJ , MatthesU , PawlakF , HoffmannK , FroschPJ , RuppertP , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. Journal of the American Academy of Dermatology1994;30(6):977‐81. [PUBMED: 8188891] ">Altmeyer 1994</a>; <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a>; <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a>, and presented the results in narrative form as in our review. It concluded that FAE have similar clinical efficacy to MTX in the treatment of moderate to severe psoriasis, based on the difference in mean change from baseline PASI score, and are more effective than placebo in the treatment of psoriasis and psoriatic arthritis. Measuring the efficacy of FAE in the treatment of psoriatic arthritis was not a prespecified outcome in our review. The <a href="./references#CD010497-bbs2-0027" title="CeglowskaU , WlodarczykA , SlomkaM . Clinical effectiveness of fumaric acid esters (Fumaderm) in psoriasis: A systematic review of literature. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands, Nov 2014:PSS6. ">Ceglowska 2014</a> review did not examine the safety of FAE to compare with our findings. The quality of included studies in <a href="./references#CD010497-bbs2-0027" title="CeglowskaU , WlodarczykA , SlomkaM . Clinical effectiveness of fumaric acid esters (Fumaderm) in psoriasis: A systematic review of literature. ISPOR 17th Annual European Congress. Amsterdam, The Netherlands, Nov 2014:PSS6. ">Ceglowska 2014</a> was scored from three to four points on the Jadad scale (range from zero, low quality, to five, higher quality). In comparison, our review determined the evidence to be of low quality when FAE were compared with placebo and very low quality when FAE were compared with MTX using the Cochrane GRADEpro tool. </p> <p>The findings in our review reinforce the statement mentioned in the European S3 guidelines that "although the use of fumarates for psoriasis has been evaluated in clinical trials, only a small number of these have followed the criteria of evidence‐based medicine" (<a href="./references#CD010497-bbs2-0057" title="PathiranaD , OrmerodAD , SaiagP , SmithC , SpulsPI , NastA , et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2009;23(Suppl 2):1‐70. [MEDLINE: 19712190] ">Pathirana 2009</a>). The guidelines included a few open label non‐RCTs, which provided some data on the long‐term safety of FAE; we did not include these in our review, which was restricted to relatively short RCTs. </p> <p>An observational prospective study by <a href="./references#CD010497-bbs2-0067" title="WalkerF , AdamczykA , KellererC , BelgeK , BruckJ , BernerT , et al. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life. British Journal of Dermatology2014;171(5):1197‐1205. [MEDLINE: 24813676] ">Walker 2014</a> examined the effectiveness, dosing, and adverse effects of Fumaderm®, the marketed brand of FAE, in daily practice. Biogen Idec GmbH, the manufacturer of Fumaderm®, funded it. The study recruited 249 adult participants with psoriasis who started Fumaderm® during their routine clinical care from 78 German dermatology centres and followed them up at 3, 6, and 12 months. It was reported that mean PASI and dermatology life quality index (DLQI) scores in the study population decreased by 66.6% and 67.2% at 12 months, respectively. In comparison, 1 of our included studies, <a href="./references#CD010497-bbs2-0004" title="MrowietzU , ReichK , SpellmanMC . Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study. Journal of the American Academy of Dermatology2006;54(Suppl):AB202. MrowietzU , SpellmanM . Dimethyl Fumarate (BG00012) as an Oral Therapy for Moderate to Severe Psoriasis: Results of a Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (Abstract 406). 35th Annual ESDR Meeting 22‐24th September 2005, Tübingen, Germany. Journal of Investigative Dermatology2005;125(3 Suppl):A69. MrowietzU , SpellmanMC . Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects (Abstract P06.97). The 14th Congress of the European Academy of Dermatology and Venereology, London,UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2005;19(Suppl 2):187. OrtonneJP , van deKerkhofP , MrowietzU . A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis (Abstract P013). 4th European Association of Dermatology &amp; Venereology (EADV) Spring Symposium. Saariselka, Lapland, Finland, Feb 9th‐12th 2006. 2006:P‐013. ">Mrowietz 2006</a>, reported 47% improvement in mean Skindex‐29 score at 16 weeks. The <a href="./references#CD010497-bbs2-0067" title="WalkerF , AdamczykA , KellererC , BelgeK , BruckJ , BernerT , et al. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life. British Journal of Dermatology2014;171(5):1197‐1205. [MEDLINE: 24813676] ">Walker 2014</a> study did not report PASI 50 at 12 or 16 weeks to allow comparison with our findings. Of the 249 participants in this report, 104 dropped out, but the study only documented reasons for this for 76 participants. Among these, 43.4% dropped out because of adverse effects. This rate was measured after 1 year of treatment whereas <a href="./references#CD010497-bbs2-0006" title="PeetersAJ , DijkmansBA , van derSchroeffJG . Fumaric acid therapy for psoriatic arthritis. A randomized, double‐blind, placebo‐controlled study. British Journal of Rheumatology1992;31(7):502‐4. [PUBMED: 1628175] PeetersAJ , DijmansBAC , van derSchroeffJG . Favourable effect of fumaric acid treatment in psoriatic arthritis: A double‐blind placebo‐controlled study [Gunstig effect van fumaarzuurtherapie bij arthritis psoriatica: een dubbelblind, placebo‐gecontroleerd onderzoek]. Nederlands Tijdschrift Voor Geneeskunde1992;136(49):2428‐31. [EMBASE: 1993004024] ">Peeters 1992</a> and <a href="./references#CD010497-bbs2-0002" title="Fallah AraniS , NeumannH , HopWC , ThioHB . Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. British Journal of Dermatology2011;164(4):855‐61. [PUBMED: 21175564] ">Fallah Arani 2011</a> measured the dropout rates because of adverse effects at 16 weeks and reported them as affecting 15.4% (2 of 13 participants) and 3.8% (1 of 26 participants), respectively. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010497-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010497-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD010497-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD010497-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FAE vs placebo, Outcome 1 AEs leading to treatment discontinuation." data-id="CD010497-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 FAE vs placebo, Outcome 1 AEs leading to treatment discontinuation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FAE vs placebo, Outcome 2 PASI 50." data-id="CD010497-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 FAE vs placebo, Outcome 2 PASI 50.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FAE vs placebo, Outcome 3 Common nuisance AEs (not leading to treatment discontinuation)." data-id="CD010497-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 FAE vs placebo, Outcome 3 Common nuisance AEs (not leading to treatment discontinuation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FAE vs MTX, Outcome 1 PASI score." data-id="CD010497-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 FAE vs MTX, Outcome 1 PASI score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FAE vs MTX, Outcome 2 AEs leading to treatment discontinuation." data-id="CD010497-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 FAE vs MTX, Outcome 2 AEs leading to treatment discontinuation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FAE vs MTX, Outcome 3 PASI 50." data-id="CD010497-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 FAE vs MTX, Outcome 3 PASI 50.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FAE vs MTX, Outcome 4 PASI 75." data-id="CD010497-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 FAE vs MTX, Outcome 4 PASI 75.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FAE vs MTX, Outcome 5 PASI 90." data-id="CD010497-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 FAE vs MTX, Outcome 5 PASI 90.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010497-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/urn:x-wiley:14651858:media:CD010497:CD010497-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_t/tCD010497-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FAE vs MTX, Outcome 6 Common nuisance AEs (not leading to treatment discontinuation)." data-id="CD010497-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 FAE vs MTX, Outcome 6 Common nuisance AEs (not leading to treatment discontinuation).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/media/CDSR/CD010497/image_n/nCD010497-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010497-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FAE compared with placebo for psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FAE compared with placebo for psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriasis<br/> <b>Setting:</b> 2 reports from the Netherlands, 1 from Poland, and 2 international multicentre studies.<br/> <b>Intervention:</b> FAE<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FAE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis))</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>PASI score reduced from a mean of 21.57 to 10.77 (FAE) and remained constant (placebo) (1 study, 99 participants; P &lt; 0.0001); median reduction of 71% (FAE) and 6% (placebo) (1 study, 144 participants; P &lt; 0.001); and median reduction of 67.8% (FAE) and 10.2% (placebo) (1 study, 175 participants; P &lt; 0.001) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All 3 studies reported significant benefit with FAE at week 12 (1 study) and week 16 (2 studies), but data could not be pooled in a meta‐analysis because of different ways of PASI score reporting </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs leading to treatment discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 participants withdrew from the FAE group (n = 13) compared with no dropouts in the placebo group (n = 14) (RR 5.36, 95% CI 0.28 to 102.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW³<sup>,</sup> ⁴ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome reported at week 16. Unclear if any of the reported AEs were 'serious'</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL)<br/> assessed with Skindex‐29 (range 0 to 100; higher scores indicate lower level of QoL) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean scores reduced from 54.7 at baseline to 27 at week 16 in the FAE group (n = 105) and from 54.0 to 51.1 in the placebo group (n = 70) (P &lt; 0.001) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The reporting abstract did not provide the statistical values needed to calculate the mean difference with 95% CI </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common nuisance AEs (not leading to treatment discontinuation)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.72<br/> (2.45 to 9.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Most commonly stomach‐ache or cramps, diarrhoea, and flushing</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 100<br/> (39 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 50</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.55<br/> (2.80 to 7.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>247<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The meta‐analysis included participants who received 720 mg DMF</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 100<br/> (39 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI 75</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>PASI 75 was attained by 39% of participants in the FAE group (n = 105) and 1% of those on placebo (n = 70) (1 study, week 16); and by 42% on FAE (n = 36) compared with 11% on placebo (n = 36) (1 study, week 12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW¹<sup>,</sup> ⁵ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported to be a statistically significant difference, but data were not pooled because of significant heterogeneity (I² statistic = 77%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI 90 ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured in the included studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AEs:</b> adverse effects; <b>CI:</b> confidence interval; <b>DMF:</b> dimethyl fumarate; <b>FAE:</b> oral fumaric acid esters; <b>PASI:</b> Psoriasis Area and Severity Index; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial; <b>OR:</b> odds ratio; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level due to risk of publication bias; data were obtained from abstract(s); full report(s) not available.<br/> ²Downgraded one level due to limitations in design; high risk of performance and detection bias.<br/> ³Downgraded one level due to indirectness; the study was designed for psoriatic arthritis where all participants also had psoriasis so may not be directly applicable to those with moderate to severe psoriasis.<br/> ⁴Downgraded two levels for imprecision; small sample size and very wide confidence interval that included the possibility of an effect in either direction (crosses line of no effect).<br/> ⁵Downgraded one level due to risk of bias; insufficient reporting. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FAE compared with placebo for psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010497-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FAE compared with MTX for psoriasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FAE compared with MTX for psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psoriasis<br/> <b>Setting:</b> Departments of Dermatology, Rotterdam and Eindhoven, the Netherlands.<br/> <b>Intervention:</b> FAE<br/> <b>Comparison:</b> MTX </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with MTX</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FAE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis))</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PASI score was 6.7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean PASI score in the intervention group was 3.8 more (0.68 more to 6.92 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW ¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASI score was measured at week 12. The study reported no significant difference between FAE and MTX based on mean change from baseline </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AEs leading to treatment discontinuation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/> (0.02 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (FAE = 26; MTX = 25). The main reasons were elevated liver enzymes with MTX and diarrhoea with FAE. No serious AEs occurred in either group </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/> (0 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL was not assessed</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common nuisance AEs (not leading to treatment discontinuation)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.77 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only flushing was significantly more reported with FAE. Occurance of other AEs including laboratory findings were not significantly different </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<br/> (77 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 50</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.41 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (MTX = 25; FAE = 26)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 100<br/> (25 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 75</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/> (0.28 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (MTX = 25; FAE = 26)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 100<br/> (7 to 55) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>PASI 90</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.05 to 4.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> <p>¹<sup>,</sup> ²<sup>,</sup> ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on a small sample size (MTX = 25; FAE = 26)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/> (0 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AEs:</b> adverse effects; <b>CI:</b> confidence interval; <b>FAE:</b> oral fumaric acid esters; <b>PASI:</b> Psoriasis Area and Severity Index; <b>MTX</b> : methotrexate; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial; <b>OR:</b> odds ratio; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded one level for imprecision due to small sample size.<br/> ²Downgraded one level for study design due to the dose of MTX.<br/> ³Downgraded one level for study design due to study being open label. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FAE compared with MTX for psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010497-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Term</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Description</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adaptive immune system</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immune cells that recognise specific infectious agents and secrete inflammatory cytokines in response </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alkaline phosphatase</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme made mostly in the liver and bones, which may indicate liver damage or bone disease if raised in the blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Angiogenic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Promoting new blood vessel formation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Apoptosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death of a cell</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arthralgia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Joint pain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Atherosclerosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Build up of fibrous and fatty material inside the arteries</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Axial skeleton</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The group of bones found along the central axis of the human body, such as the spine</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bilirubin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A yellow‐orange compound produced by the breakdown of haemoglobin from red blood cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biologic treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of drug engineered to alter a specific element of the inflammatory cascade</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemokines</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small protein molecules secreted by cells that attract other inflammatory cells to the area </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Contraindication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A situation that serves as a reason to withhold a certain treatment or procedure because it may be harmful to a patient </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Creatinine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chemical waste product that comes from diet and normal breakdown of muscles and is excreted by the kidneys. It may indicate impaired kidney function if raised in the blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cytokines</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small protein molecules secreted by cells to communicate with neighbouring cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dendritic cells</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of immune cell that act as a messenger between the innate and adaptive immune systems </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eosinophil</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A cell of the immune system that combats parasite infections and is also involved in reactions to some drugs </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Eosinophilia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased number of eosinophils in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythrocytes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Red blood cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fumarates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Organic compounds widely found in nature that play a role in citric acid (Krebs) cycle</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gamma glutamyltransferase</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme produced by many tissues, mainly the liver; if raised, it may indicate liver disease </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Immunosuppressive</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in the activity of the immune system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A protective response to injury mediated by cells of the immune system, characterised in the skin by redness, heat, swelling, and pain or itch </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Innate immune system</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immune cells and proteins, such as complement, that fight infectious agents in a non‐specific way </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leucocytes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>White blood cells that are part of the immune system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leukocytopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased number of white blood cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Locus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The position of a gene on a chromosome</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lymphocyte</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of white blood cell involved in the adaptive immune system, which can be subdivided into T cells and B cells </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lymphocytopenia or lymphopenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased number of lymphocytes in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major histocompatibility complex</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cell surface molecules involved in recognition of pathogens and tolerance to an individual's own proteins </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Platelet</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of circulating blood cell that helps to form blood clots and stop bleeding (also called thrombocytes) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proteinuria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The presence of abnormal quantities of protein in the urine</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psoriasis Area and Severity Index (PASI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A measure of psoriasis severity that includes the extent of body surface area involvement and the maximum thickness, redness, and scaliness of the plaques. Scores range from 0 to 72, and a higher score indicates more severe disease </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scaly</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silvery‐white flakes of skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum creatinine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The level of creatinine in the blood plasma</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>T (helper) cell</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of white blood cell involved in the adaptive immune system</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased number of platelets in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transaminases</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enzymes normally found in the liver and heart, which may indicate liver or heart disease if raised in the blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Triglycerides</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A type of fat in the blood</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinalysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urine analysis</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/full#CD010497-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010497-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">FAE vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 AEs leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PASI 50 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [2.80, 7.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Common nuisance AEs (not leading to treatment discontinuation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">FAE vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010497-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">FAE vs MTX</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 PASI score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 AEs leading to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PASI 50 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PASI 75 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PASI 90 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Common nuisance AEs (not leading to treatment discontinuation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">FAE vs MTX</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010497.pub2/references#CD010497-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010497.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010497-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010497-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010497-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010497-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010497-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD010497-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010497-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010497\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010497\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010497\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010497\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010497\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010497.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010497.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010497.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010497.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010497.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716541201"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010497.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716541205"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010497.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da2042e889379',t:'MTc0MDcxNjU0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 